Skip to main content
Acta Myologica logoLink to Acta Myologica
. 2020 Dec 1;39(4):245–265. doi: 10.36185/2532-1900-028

Panorama of the distal myopathies

Marco Savarese 1,2, Jaakko Sarparanta 1,2, Anna Vihola 1,2,3, Per Harald Jonson 1,2, Mridul Johari 1,2, Salla Rusanen 1,2, Peter Hackman 1,2, Bjarne Udd 1,2,4,
PMCID: PMC7783427  PMID: 33458580

Abstract

Distal myopathies are genetic primary muscle disorders with a prominent weakness at onset in hands and/or feet. The age of onset (from early childhood to adulthood), the distribution of muscle weakness (upper versus lower limbs) and the histological findings (ranging from nonspecific myopathic changes to myofibrillar disarrays and rimmed vacuoles) are extremely variable. However, despite being characterized by a wide clinical and genetic heterogeneity, the distal myopathies are a category of muscular dystrophies: genetic diseases with progressive loss of muscle fibers. Myopathic congenital arthrogryposis is also a form of distal myopathy usually caused by focal amyoplasia.

Massive parallel sequencing has further expanded the long list of genes associated with a distal myopathy, and contributed identifying as distal myopathy-causative rare variants in genes more often related with other skeletal or cardiac muscle diseases.

Currently, almost 20 genes (ACTN2, CAV3, CRYAB, DNAJB6, DNM2, FLNC, HNRNPA1, HSPB8, KHLH9, LDB3, MATR3, MB, MYOT, PLIN4, TIA1, VCP, NOTCH2NLC, LRP12, GIPS1) have been associated with an autosomal dominant form of distal myopathy. Pathogenic changes in four genes (ADSSL, ANO5, DYSF, GNE) cause an autosomal recessive form; and disease-causing variants in five genes (DES, MYH7, NEB, RYR1 and TTN) result either in a dominant or in a recessive distal myopathy. Finally, a digenic mechanism, underlying a Welander-like form of distal myopathy, has been recently elucidated. Rare pathogenic mutations in SQSTM1, previously identified with a bone disease (Paget disease), unexpectedly cause a distal myopathy when combined with a common polymorphism in TIA1.

The present review aims at describing the genetic basis of distal myopathy and at summarizing the clinical features of the different forms described so far.

Key words: distal myopathy, rimmed vacuoles, myofibrillar myopathy

Introduction

The term distal myopathy refers to a long list of genetic muscle diseases presenting at the onset with weakness of distal extremities, usually combined with progressive atrophy of the corresponding distal muscles. Other muscles, including proximal muscles and/or cardiac and respiratory muscles, can be affected at a later stage of the disease. The clinical phenotype is extremely variable, ranging from severe forms with earlier onset and loss of ambulation to very mild late adult onset forms. Other muscle diseases (genetically determined or acquired) may present with a distal phenotype, making the diagnostic process more complex.

Although two patients with weakness in hands and in legs or feet were first described as distal myopathy by Gowers over 100 years ago 1, only in 1998 the first genetic defect underlying a distal myopathy was identified 2. Ten years ago, in 2010, only fourteen causative genes were known. In the last years, massive parallel sequencing has contributed to identify disease-causing variants in novel genes and to elucidate the first example of a digenic mechanism causing a distal myopathy (Tab. I). At the same time, the number of causative variants, identified in large resequencing projects, has exponentially increased 3-7. Interestingly, most currently known genes are also responsible for separate different clinical entities, confirming the extreme phenotypic divergence observed in the field of genetic myopathies 8.

More advanced histopathological techniques and refined cell and molecular biology studies have resulted in a better understanding of the pathophysiology of distal myopathies. Clinical, histopathological, and imaging features of each form have been partly clarified, addressing the diagnosis, and supporting a proper interpretation in case of novel variants identified in previously known genes.

Adult – late onset distal myopathies

Welander distal myopathy (WDM) – TIA1

WDM was first described in several Swedish families in 1951 as an autosomal dominant late adult-onset (usually over 50 years) disease with a prominent early involvement of fingers and wrist extensors 9. As the disease progresses, weakness involves also finger flexors, toe and ankle extensors. The disease course is usually slowly progressive, and patients remain ambulant. Histopathology features include rimmed vacuoles.

A missense variant (p.E384K) in TIA1 gene causing the disease was identified in 2013 10. TIA1 encodes an RNA-binding protein involved in the alternative splicing of specific pre-mRNAs 11-14, and is a key molecule in stress granules, regulators of RNA-translation metabolism that show altered dynamics in WDM 10.

Digenic SQSTM1 and TIA1 mediated distal myopathy

Patients with a Welander distal myopathy phenotype but negative for causative rare mutations in TIA1 were discovered to have instead a common polymorphism in the TIA1, which, with a population frequency of 1%, could not be the cause of the disease. Further gene panel sequencing in these patients showed the presence of SQSTM1 mutations previously known to cause the Paget’s disease of the bone, a dominant disease with reduced penetrance 15. Functional studies showed that the SQSTM1 gene product, p62, interferes with the same stress granule dynamics pathway as TIA1 explaining the background for the digenic mechanism 15. This genetic combination of rare SQSTM1 causative variants and the common TIA1 polymorphism did not result in a Paget disease of the bone but caused the canonical Welander phenotype. On the other hand, a cohort of 50 patients with Paget disease of the bone carrying the same SQSTM1 mutations did not have the TIA1 polymorphism 15.

Tibial muscular dystrophy (Udd myopathy) – the first human titinopathy

Tibial muscular dystrophy (TMD) or Udd myopathy was described in 1993 in Finnish patients 16. Weakness in ankle dorsiflexion and atrophy of anterior lower leg muscles (often asymmetric) start after age of 35 or much later. Progression is slow and walking is usually preserved. Extensor digitorum brevis and hand muscles are normally spared. Serum CK is normal or mildly elevated and muscle imaging shows fatty degeneration in anterior tibial muscles and at later stage in all long toe extensors, hamstring and medial gastrocnemius muscles.

Muscle biopsy shows myopathic changes with acid phosphatase, ubiquitin, p62 and LC3 positive in the affected muscles, but in preserved muscles there is only a slight increase of internal nuclei.

In Finnish TMD patients, a common founder mutation (FINmaj) in the last exon of titin gene (TTN) was identified in 2002 17. FINmaj is a complex 11-bp insertion–deletion resulting in substitution of four amino acids without any frameshift and preserving the downstream amino acid sequence. Following the FINmaj identification, missense variants in the same exon (364) were also identified in non-Finnish patients 17-19.

TTN gene encodes titin, the third filament system of the sarcomere 20. Titin interacts with several important proteins, including calpain-3 that binds the C-terminal portion of titin 21,22. Through a large number of alternative splicing events, TTN encodes for a large number of different transcripts, developmental-stage or tissue specific 23,24. Reflecting the size and complexity of titin, causative variants result in allelic diseases affecting skeletal muscle, heart or both of them, referred to as ‘titinopathies’ 25,26. Dominant titinopathies include the aforementioned TMD, and the hereditary myopathy with early respiratory failure (HMERF) caused by missense variants in exon 344 17,27-29. Recessive titinopathies include a wide spectrum of diseases with a prenatal, congenital, childhood or later onset 30,31. A recessive form of early/juvenile onset recessive distal titinopathy is further discussed below in this review. With the increasing number of reported patients, first insights on the genotype-phenotype correlation are achieved 30. TTN variants are also associated with dilated and hypertrophic cardiomyopathy 32,33.

Vocal cord and pharyngeal distal myopathy – MATR3

First described in a large North American family 34 and later in a large Bulgarian pedigree 35, vocal cord and pharyngeal distal myopathy (VCPDM) is characterized by adult-onset (between 35 and 60 years) distal weakness and weakness of vocal cord and pharyngeal muscles. Limb weakness can be asymmetric and the phenotype is highly variable in terms of age of onset, progression and muscle weakness distribution 34,36,37. Most patients develop respiratory failure 38. CK levels are normal or mildly elevated. EMG shows myopathic changes and rimmed vacuoles are present in the biopsy. Muscle MRI shows a predominant involvement of the lower legs both anterior and posterior compartment and hamstrings in thighs 39.

The underlying re-occurring p.S85C mutation was identified in MATR3 gene 35. MATR3 encodes matrin-3, a protein located in the nuclear matrix where it regulates several processes related to gene expression, RNA splicing and export of RNA and nuclear proteins 40,41. Variants in MATR3 have also been identified in patients with amyotrophic lateral sclerosis (ALS) 42.

Distal Actininopathy – ACTN2

Distal actininopathy is an autosomal dominant, adult onset distal myopathy starting usually with foot drop. The disease later progresses to proximal lower limb muscles while upper limbs remain relatively spared 43. Serum CK levels are mildly elevated and muscle biopsy shows rimmed vacuoles with some myofibrillar disarrays and undulation of the Z-disk on electron microscopy 43.

The underlying genetic defects in the four families reported so far are heterozygous missense variants in the ACTN2 gene. ACTN2 encodes alpha-actinin2, a structural molecule of the Z-disks that interacts with titin and acts a scaffold of many other Z-disk located proteins such as myotilin 44-47.

Variants in ACTN2 also cause congenital myopathy with structured cores and Z-line abnormalities 48. Moreover, dilated cardiomyopathy and hypertrophic cardiomyopathy have been associated with missense variants in ACTN2 49-53.

Distal Myopathy with sarcoplasmic bodies – MB

In 1980 Edström et al. published a Swedish family with this title 54. Only recently, the genetic cause of the disease was identified with one unique causative variant in Myoglobin (MB), reoccurring in several unrelated families 55. In these later studied families, the characteristic muscle pathology was evident but the clinical phenotype was more proximo-distal and not particularly distal 55.

Oculopharyngeal distal myopathy OPDM – CGG and GGC expansions

The peculiar combination of severe adult onset distal atrophies in limb muscles and facial weakness, ptosis and dysphagia can occur both in dominant and recessive families and in sporadic patients 56,57. In the studied patients, the muscle pathology is a rimmed vacuolar myopathy. In the two last years the cause of many Asian dominant families have been clarified as caused by triplet repeat expansions, both CGG and GGC, in three different genes NOTCH2NLC, LRP12 and GIPC1 58-61. The repeats are translated into aggregating protein products and the host gene functions are not supposed to contribute to the disease mechanism.

PLIN4 mutated distal myopathy – PLIN4

A large Italian family with an autosomal dominant adult-onset distal myopathy and histopathological features of rimmed vacuoles was first described in 2004 62. Linkage analysis suggested that the causative gene could have been localized in the 19p13.3 locus 62.

Recently, Ruggieri et al. identified the underlying genetic defect in the PLIN4 gene, encoding for perilipin-4 63. Thirty-one repeats of 99 nucleotides in exon 4 of PLIN4 encode the 31x33 amino acid amphipathic domain of perilipin-4. An expansion of the normal repeat to 40 × 99 bases, resulting in 297 (9 × 33) extra amino acids, has been identified in the affected members of the family.

Perilipin-4 is a member of the perilipin family, a group of proteins that coat the surface of lipid droplets 64. Perilipin-4 is highly expressed in skeletal muscle with a possible role in lipid metabolism. The identified repeat expansion in patients with PLIN4-related distal myopathy seems to cause a misfolding and leads to protein accumulation in vacuoles disrupting the myofibrillar organization 63.

VCP distal myopathy – VCP

Initially described by Palmio and colleagues in a large dominant Finnish family, VCP-related distal myopathy has an onset in mid-adulthood mainly affecting anterior leg muscles 65. After 25 years of disease, the patients became affected by a progressive frontotemporal dementia. None of the patients had signs of Paget disease of the bone. Serum CK levels are normal or slightly elevated. Myopathic changes with rimmed vacuoles are observed in the muscle biopsy. MRI shows degenerative changes of anterior lower leg muscles.

Although a clinical variability has been observed 66-73, the most common phenotype of pathogenic VCP variants is proximal myopathy with scapular winging, Paget disease and frontotemporal dementia (IBMPFD) 74-76.

Myofibrillar distal myopathies

Distal myopathy with myotilin defect – MYOT

A late-onset distal myopathy has been associated with heterozygous variants in MYOT gene 77-79. The first symptoms, weakness of ankle dorsiflexion and/or calf muscles, occur after age 50 years but, despite late onset, the further progression can be rapid. Respiratory and cardiac muscles are spared.

Histopathological features are consistent with myofibrillar myopathy and include rimmed and non-rimmed vacuoles, and myofibrillar disorganization with myotilin accumulations 79-81. Muscle imaging shows that soleus is typically the first muscle affected followed by tibialis anterior and gastrocnemius medialis muscles 82,83.

The most common causative variants in MYOT are missense changes affecting serine and threonine amino acids in the serine rich domain. MYOT gene encodes myotilin, a key component of the Z-disc, directly binding F-actin 84. Some patients have been described as affected by a dominant limb-girdle muscular dystrophy (previously LGMD1A) 85,86, but distal myopathy is the main phenotype. A proximal muscle involvement is only observed in later stages or in homozygosity for known dominant variants 87,88. The term ‘spheroid body myopathy’ was also used since the protein aggregates in some cases have the corresponding shape 89,90.

Late onset distal myopathy (Markesbery-Griggs, Zaspopathy) – LDB3

The dominant LDB3-related distal myopathy usually starts with ankle weakness after the age of 40 years with later involvement of proximal muscles 91-94. Cardiomyopathy can occur very late; facial and respiratory muscles are preserved. Muscle biopsy reveals myofibrillar myopathy with rimmed and non-rimmed vacuoles 95. Myofibrillar protein accumulations are similar with myotilinopathy and desminopathy 96.

LDB3 encodes the lim domain-binding 3 protein, also called Z-band alternatively spliced PDZ motif-containing protein (ZASP) that interacts with other Z-disk proteins 97,98. Hypertrophic and dilated cardiomyopathies (with or without left ventricular noncompaction) are allelic disorders 99,100.

Desminopathy – DES

Desmin-related distal myopathy is a myofibrillar myopathy with cytoplasmic accumulation of desmin in cardiac and skeletal muscles. The first family was described in 1943 long before the gene was known 101,102. Cardiomyopathy and cardiac conduction defects are frequent, and the weakness/atrophy involves both hands and lower legs with later spread to proximal muscles. MRI shows the early involvement of peroneal muscles followed by tibialis anterior, gastrocnemius and soleus muscles 80,82. CK is usually slightly elevated.

The fist causative variants in DES were identified in 1998 103. DES encodes desmin, a protein of the intermediate filament connecting Z-band with the plasmalemma and the nucleus104. As suggested by a recent study, desmin forms seeding-competent amyloid that is toxic to myofibers and disease-causing mutations enhance the amyloid formation 105. Most patients have a dominant disease with onset in early adulthood but a later onset is possible 106. Rare cases with a recessive, more severe, form have been reported 107. Dominant cardiomyopathy without skeletal muscle disease, scapuloperoneal and other phenotypes, due to the increasing number of causative variants identified, are also reported 108-112.

Alpha-B crystallin-mutated distal myopathy – CRYAB

In 1998, Vicart and colleagues identified the first causative variant in the CRYAB gene causing a myopathy with accumulation of aggregates of desmin 113. In 2003, Selcen et al described patients with a generalized proximal and distal myopathy affecting also the cardiac and respiratory function and carrying mutations in CRYAB 114D. In 2010 and in 2012, two studies identified patients with CRYAB mutations and a distal adult-onset myofibrillar myopathy 115,116. CRYAB-related distal myopathy mainly involves the anterior part of the distal leg at the early stage and progresses with a milder proximal weakness. Cataracts are the hallmark and dysphagia, dysphonia, respiratory failure, and cardiomyopathy may be associated. Muscle MRI shows fatty degenerative changes in tibialis anterior, gastrocnemius medialis muscles and vastus muscles 82,115,117,118.

CRYAB encodes alpha-B-crystallin, also called HSPB5, a member of the small heat-shock protein family, a molecular chaperone that interacts with desmin in the assembly of intermediate filaments 119-122.

Causative CRYAB variants also cause a dominant dilated cardiomyopathy, congenital cataract (dominant and recessive) and a more severe, usually recessive myopathy (fatal infantile hypertonic myofibrillar myopathy) 123-127.

Early adult onset distal myopathies

Miyoshi myopathy – DYSF

Miyoshi and colleagues first described patients in the sixties with early adult-onset weakness, myalgia and atrophy in calf muscles 128. Serum creatine kinase (CK) is highly elevated already in the early stages of the disease or even in presymptomatic patients. Muscle imaging shows marked involvement of posterior lower legs. Muscle biopsy shows myopathic changes with necrotic fibers in the calf muscles and inflammation is a common finding.

Dysferlin (DYSF) as causative gene with biallelic recessive mutations was identified in 1998 2. Dysferlin is a ubiquitous transmembrane protein with a high skeletal muscle expression. The protein most probably acts in calcium-mediated sarcolemmal fusion events and resealing 129-131. Dysferlin expression by immunostaining or western blot (even from blood leucocytes) is useful in the diagnostic process, although the protein can be also secondarily reduced 132,133.

Myoshi myopathy and LGMDR2 Dysferlin-related (previously LGMD2B), one of the most common LGMD form in several countries 4,134,135, are allelic diseases with overlapping symptoms and signs 136,137. LGMD patients have a more proximal involvement at the onset but, after 20 years of disease progression, the two phenotypes usually merge as dysferlinopathies 138-140.

Recessive distal titinopathy – TTN

Some nonsense, small indels causing a frameshift or splice site variants in the last and second last exons of TTN, initially also thought to cause dominant TMD because of dominant-looking pedigrees, later proved to be recessive 141-145. The presence of second causative variants in trans explains the novel entity of early/juvenile onset recessive distal titinopathy, a more severe condition than the late onset TMD 141-143. In some families, multiple second causative variants segregating with the disease would mimic the presence of a dominant inheritance, making the diagnosis even more complex 141,142,146.

The complexity of TTN gene may result in elusive variants not identified on DNA by the traditional pipelines 147. Second tier tests, such as copy number variant (CNV) analysis and RNA sequencing, contribute to identify unrecognized pathogenic variants 148-152.

Distal myopathy with rimmed vacuoles (Nonaka or GNE myopathy) – GNE

Independently described by Nonaka et al. and by Argov and Yarom, the GNE distal myopathy is a rimmed vacuolar recessive myopathy with an early adult onset 153,154. It first affects the anterior compartment of lower legs and thigh hamstring muscles with sparing of the quadriceps, but the progression is rather severe, and half of the patients loose ambulation within 10 years. Serum creatine kinase is mildly elevated and muscle histopathology is characterized by rimmed vacuoles.

The causative gene (GNE) was identified in 2001 155 and, since then, patients have been reported worldwide. GNE encodes an epimerase-kinase enzyme involved in the sialic acid biosynthesis. Glycoproteins and glycolipids located in the membrane often undergo a sialic acid modification that seems to be crucial for their function 156. Nevertheless, in a recent study, no consistent major change in sialylation has been observed comparing patients and matched control samples, suggesting that the pathophysiology of the disease is still unclear 157.

More than 180 variants are currently known and founder mutations first reported from Middle East and Japan have been described in many populations 158-163. GNE is susceptible to Alu-mediated recombination, and copy number variants (CNV) have been reported suggesting the utility of second-tier tests in case of an uninformative sequencing analysis aiming at the identification of single nucleotide variants 164-167. Moreover, a vast clinical heterogeneity, only partly explained by the GNE genotype, is observed in families with GNE mutations 160,168-170.

Sialuria is an allelic dominant metabolic disease characterized by the accumulation of N-acetylneuraminic acid (NeuAc) due to missense variants in GNE 171.

Distal ABD-filaminopathy – FLNC

A large Australian family with a dominant, adult-onset, slowly progressive distal myopathy was described in 2005 by Williams and colleagues 172. In a second Italian family with otherwise similar phenotype reported by Duff et al. cardiac involvement was also present 173. Weakness of handgrip is the usual presentation followed by calf muscle plantar flexion weakness. The progression is slow, and patients remain ambulant. CK is normal or mildly elevated, and muscle MRI shows fatty replacement in posterior compartment of lower legs. Histopathology is unspecific myopathic without vacuoles or myofibrillar abnormalities.

Combining linkage data and resequencing of candidate genes in these two families, two different missense changes in the N-terminal actin-binding domain (ADB) of FLNC were identified 173. The FLNC gene encodes filamin, an actin ligand that plays an important role in mechanical stabilization, mechanosensation and intracellular signalling through a large network of interactors 174,175. Mutations in other parts of the gene may cause late onset myofibrillar myopathy with generalized weakness and cardiomyopathy 176-178. After the gene identification in 2011, novel FLNC causative variants have been identified, expanding the spectrum of FLNC-related myopathies 179-181.

Recent findings suggest a more complex genotype-phenotype correlation. A missense variant, p.M222V, in the N-terminal actin-binding domain, causing a distal myofibrillar myopathy, has been reported 182. Another missense change, p.C203Y, has been recently found to cause an upper limb distal myopathy with nemaline bodies 183.

DNAJB6 distal myopathy – DNAJB6

The disease was originally reported by Servidei and colleagues in a large Italian family with onset of ankle weakness between the second and sixth decades of life 184, and usually progressing to proximal muscles and upper limbs. Muscle biopsy showed dystrophic changes and rimmed vacuoles. In the Italian family, the causative variant was found in DNAJB6, in a different locus from the one initially reported 185. DNAJB6 encodes a ubiquitously expressed member of the DNAJ/HSP40 family of co-chaperones 119,186. Mutations in DNAJB6, specifically in the G/F domain, cause more often a proximal myopathy (LGMD1D) 187-193. Recently, a form of DNAJB6-related distal calf-predominant myopathy has been reported in patients with particular mutations in the N-terminal J-domain 194.

Rimmed vacuolar neuromyopathy – HSPB8

Ghaoui and colleagues reported two families with a dominant HSPB8-related disease showing early adult neurogenic leg weakness and progressing towards a distal and proximal myofibrillar and rimmed vacuolar myopathy in the later stage of the disease 195. EMG revealed denervation in the distal lower limbs and myopathic proximal changes. MRI of the lower limb muscles showed first diffuse neurogenic changes in gastrocnemius, deep toe flexors, and peroneus with later fatty replacement in proximal thigh and lower legs muscles.

The HSPB8 gene encodes the small heat-shock protein-beta 8, acting as stress protein with a chaperone-like activity and part of the chaperone-assisted selective autophagy (CASA) complex 119,196. HSPB8 missense variants had been previously associated with distal hereditary motor neuropathy 2A (dHMN2A) and Charcot-Marie-Tooth disease (CMT2L) 197-201. The myofibrillar myopathy with aggregates and rimmed vacuoles mimics the histopathological changes seen in myopathies caused by defects in BAG3 and DNAJB6 202,203.

Later other families with a combined neuromuscular disorder, encompassing dHMN and MFM have been described204. In one family decrease of TARDBP mRNA levels causing a consistent alteration of TDP–43-dependent splicing was reported 204. Recently, a novel HSPB8 variant has been found in a patient with limb-girdle myopathy without associated neuropathy 205.

ANO5 distal muscular dystrophy – ANO5

Distal anoctaminopathy has an age of onset in early/mid adulthood (18-40 years) 206,207. Early manifestations include difficulties in sport activity and in walking on tiptoes but often the clinical presentation is mild, or the disease does not even result in overt clinical signs. The early stage hypertrophy of calf muscles progresses into muscle atrophy 208. At a later stage, proximal muscle weakness and wasting is observed. Typically, the cardiac muscle is spared. CK levels are usually highly elevated (over 10 times the upper limits). Non-specific myopathic changes with scattered necrotic fibers are observed in the muscle biopsy.

The disease is due to bi-allelic causative variants in the ANO5 gene, encoding for anoctamin-5, a putative cytoplasmic calcium-activated chloride channel, with a possible role in membrane fusion and repair 209,210. The more common phenotype of bi-allelic variants in ANO5 is late onset proximal (LGMDR12) 206,207,211-214. Variants causing ANO5-related recessive anoctaminopathies mostly result in a reduced protein expression and missense changes likely destabilize the protein, causing its degradation 215,216. We still lack a clear genotype-phenotype correlation explaining the high intrafamilial and interfamilial clinical variability observed, also considering that female patients often have a milder disease than males 206,212,217-221.

A dominant form of gnathodiaphyseal dysplasia is (GDD) an allelic disorder caused by ANO5 missense variants in heterozygosity 222,223. The pathomechanism of the ANO5-related GDD is still unclear. However, the protein seems to have an important role in the embryonic development and most probably in the osteoblast differentiation 223.

RYR1 mutated calf predominant distal myopathy – RYR1

A very mild dominant distal myopathy with preferential fatty degeneration of medial gastrocnemius, clearly shown by muscle MRI, has been recently reported in one Italian and two Finnish families 224. Some patients exhibit toe walking in the childhood with spontaneous remission. In adulthood, patients complain of exercise myalgia in the calves, and show 5-10 fold elevated CK. No limitation of walking was present even in elderly patients. Muscle biopsy reveals core pathology. Three different RYR1 mutations were identified in different parts of the gene, which encodes ryanodine receptor 1, a calcium release channel of the sarcoplasmic reticulum that, together with sarcolemmal voltage-gated calcium channels (DHPR), is responsible for the excitation-contraction coupling.

Dominant and recessive mutations in the RYR1 gene present with a multitude of phenotypes including malignant hyperthermia (MH) susceptibility and congenital central core disease (CCD), centronuclear myopathy, multiminicore myopathy, congenital fibre type disproportion, axial myopathy, King-Denborough syndrome, atypical periodic paralysis and exertional rhabdomyolysis/myalgia 225-235. A childhood-onset distal myopathy presenting with hand stiffness and facial weakness has been associated to bi-allelic RYR1 variants 236.

Early-childhood onset distal myopathies

Early onset distal myopathy (Laing myopathy) – MYH7

Laing myopathy was the first distal myopathy with established genetic linkage 237. The onset is in early childhood with the ankle dorsiflexor and toe extensor (hanging big toe) weakness and the disease has a slow progression. Severe forms develop scoliosis and involves proximal, neck and facial muscles. CK levels are normal or mildly elevated. The most consistent histopathology is hypotrophy of type 1 slow fibers, often combined with core/minicore lesions 238. Muscle MRI shows the involvement of anterior compartment lower leg muscles and, eventually, of the sartorius, with relative sparing of the lateral gastrocnemius muscle and rectus femoris 239-242.

In 2004 the causative variant was identified in the MYH7 gene encoding the beta heavy chain of myosin 243. Since then, a large number of causative variants in the tail of the protein were reported, with a large proportion (30%) of re-occurring de novo mutations masking the dominant effect of the variants 244-248. Causative variants in the head and neck domains at the N-terminal of the protein have been mainly associated with hypertrophic cardiomyopathy (without skeletal muscle involvement) 249-251. Variants in the ultimate C-terminal region most often result in other skeletal myopathies (hyaline body myopathy) with or without cardiac involvement 252,253. Rare recessive forms of MYH7-related myopathy have been reported 254-256.

Early onset distal myopathies with nebulin defect – NEB

Bi-allelic, mainly missense, variants in NEB gene may result in an early-onset distal myopathy with a predominant weakness of extensor muscles of feet and later hands 257,258. The progression is very slow and adult patients do not have major disability.

Muscle imaging shows a selective fatty degeneration in the anterior tibial muscles, EMG is myopathic and CK is normal or mildly elevated. Scattered and grouped atrophic fibers (that can be misinterpreted as neurogenic changes) are detectable in the biopsy of affected muscle without rods on light microscopy 258,259. Small rods associated with Z-disks may be present on electron microscopy 259.

A large in-frame deletion, dominantly inherited in a three-generation family with a distal nemaline rod/cap myopathy, was recently described 260. The in-frame deletion results in a protein of reduced size with a dominant-negative effect 260. Patients present with foot drop in childhood and the disease progresses with the involvement of distal upper limbs. CK can be slightly elevated, EMG is myopathic and muscle MRI shows fatty degeneration of the anterior compartment lower leg muscles. A large heterozygous de novo deletion in young patient with asymmetric distal and facial weakness has just been identified confirming the dominant effect of an abnormal protein (submitted).

The 183-exon NEB gene encodes nebulin, a protein of 600-900 kDa that regulates the length of actin filaments 261,262. Causative variants in NEB (mainly nonsense, out-of-frame indels or copy number variants, and splicing variants) are the most common cause of congenital nemaline myopathy 263,264. Additional allelic diseases are core rod myopathy, and fetal akinesia/lethal multiple pterygium syndrome 259,265,266.

Copy number variant (CNV) analysis and RNA sequencing are essential to identify possible elusive pathogenic NEB variants 148-150,267,268.

Early onset ADSSL distal myopathy – ADSSL

In 2016, Park and colleagues reported two unrelated Korean families with an autosomal recessive adolescent-onset distal myopathy with facial muscle weakness, mild CK elevation and rimmed vacuoles in the muscular biopsy 269,270. Two different variants in the ADSSL gene were identified by exome sequencing. The ADSSL gene encodes the muscle isozyme of adenylosuccinate synthase, the enzyme catalysing the initial reaction in the conversion of inosine monophosphate (IMP) to adenosine monophosphate (AMP) 271,272. Two following studies identified novel Korean and non-Korean (Turkish and Indian) patients, confirming the gene-disease association 273,274. Most patients presented with a distal myopathy with onset in childhood or adolescence progressing to involve weakness of proximal muscles in early adulthood. However, one patient, homozygous for a missense variant, shows a proximal myopathy with contractures and muscle atrophy, expanding the ADSSL-related spectrum of phenotypes 274.

Early onset distal myopathy with KLHL9 mutations – KLHL9

Cirak and colleagues described a German family with an autosomal distal weakness caused by a heterozygous variant in the KLHL9 gene 275. Despite extensive later studies, this gene has not been confirmed in any other myopathy families.

Other myopathies and dystrophies with distal weakness

Distal myopathy with caveolin defect – CAV3

In 2002, Tateyama and colleagues described a form of sporadic distal myopathy caused by an heterozygous missense variant in CAV3 gene 276. Since then, additional patients and further causative variants have been reported 277,278. Onset is in early adulthood, muscle atrophy and weakness are often limited to the small muscles of the hands and feet. Other features included calf hypertrophy, pes cavus, myalgias, slightly increased serum CK. EMG studies show a myopathic pattern and histological findings include nonspecific myopathic changes 278,279. CAV3 expression can be reduced.

Variants in CAV3 can also cause an isolated hyperckemia or a rippling muscle disease 280-285 and even cardiac phenotypes (hypertrophic cardiomyopathy and long QT syndrome) 286,287. Some patients with CAV3 related myopathy have been previously described as LGMD1C patients 288.

DNM2 related distal myopathy – DNM2

DNM2-related myopathy is an autosomal dominant slowly progressive centronuclear myopathy characterized by the presence of centrally located nuclei in a several muscle fibres 289. The clinical onset is usually in childhood or early adulthood 290. The distal muscle weakness is marked although facial weakness is the clinical lead to diagnosis 291-300. More severe forms, clinically resembling myotubular myopathy, have been described 301. MRI studies shows fatty infiltration of the calf muscles 302. Electromyography may show a mix pattern with myopathic and neuropathic changes.

DNM2 encodes dynamin 2, a ubiquitously expressed GTPase that is involved in endocytosis and intracellular trafficking 303-306. Dynamin 2 interacts with actin and has an active role in regulating microtubule networks and in centrosome function 307. DNM2 mutations can also cause an intermediate or axonal CMT disease with and without cataracts 308. A lethal congenital syndrome associating akinesia, joint contractures, hypotonia, skeletal abnormalities, and brain and retinal haemorrhages has been observed in three consanguineous families with a missense variant (p.Phe379Val) in homozygosity 309.

Differential diagnostics

A long range of other myopathies needs to be considered in the differential diagnostics since they may show prominent distal weakness and/or atrophy:

  • Facioscapulohumeral muscular dystrophy;

  • Myotonic dystrophy type1;

  • HMERF titinopathy (i.e. p.C31712R mutation);

  • Scapuloperoneal syndromes (FHL-1, TRIM32,…);

  • Other nemaline and rod-core myopathies (TPM2, ACTA1,…);

  • Inclusion body myositis;

  • Telethoninopathy;

  • Glycogenoses: brancher and debrancher enzyme defects;

  • Lipidosis in PNPLA2 mutated disease;

  • Mitochondrial distal myopathy (POLG1);

  • Nephropathic cystinosis;

  • Amyloid myopathy (myeloma induced).

Conclusions

Despite the huge developments in the last 20 years to uncover the genetic cause of distal myopathy, some families and patients still remain without a final diagnosis. The introduction of long read sequencing and RNA sequencing in clinical care and the constitution of large international consortia will most probably further increase the diagnostic rate 310-316.

The reason for some genetic defects to have preference for the distal limb muscles in causing loss of muscle tissue is unclear and understanding the molecular background for this preference may also harbour insight for therapeutic opportunities.

Considering the crucial advancements in the last decade, we can look forward optimistically to the upcoming decade. We will most probably identify an increasing number of digenic diseases and of genetic and non-genetic modifiers influencing the phenotype. The next challenge is to translate the genetic and molecular advancements in clinics, thereby contributing to the development of a personalized medicine aiming at providing a tailored approach to each patient with a distal myopathy 317,318.

Figures and tables

Table I.

List of distal myopathies and causative genes.

Clinical entity Gene(s) Trasmission References
Adult – late onset distal myopathies
Welander distal myopathy TIA1 AD Hackman et al., 2012
Digenic SQSTM1 and TIA1 mediated distal myopathy SQSTM1+TIA1 DG Lee et al., 2018
Tibial muscular dystrophy (Udd myopathy) TTN AD Hackman et al., 2002
Vocal cord and pharyngeal distal myopathy MATR3 AD Senderek et al., 2009
Distal Actininopathy ACTN2 AD Savarese et al., 2019
Distal Myopathy with sarcoplasmic bodies MB AD Olive et al., 2019
Oculopharyngeal distal myopathy NOTCH2NLC, LRP12 and GIPC1 AD Deng et al., 2020; Ishiura et al., 2019; Saito et al., 2020; Sone et al., 2019
PLIN4 mutated distal myopathy PLIN4 AD Ruggieri et al. 2020
VCP distal myopathy VCP AD Palmio et al 2011
Myofibrillar distal myopathies
Distal myopathy with myotilin defect MYOT AD Penisson-Besnier et al., 2006
Late onset distal myopathy
(Markesbery-Griggs, Zaspopathy)
LDB3 AD Griggs et al., 2007
Desminopathy DES AD > AR Sjoberg et al., 1999
Alpha-B crystallin-mutated distal myopathy CRYAB AD Reichlich et al. 2010
Early adult onset distal myopathies
Miyoshi myopathy DYSF AR Liu et al., 1998
Recessive distal titinopathy TTN AR Evila et al., 2017
Distal myopathy with rimmed vacuoles
(Nonaka and GNE myopathy)
GNE AR Kayashima et al., 2002
Distal ABD-filaminopathy FLNC AD Duff et al., 2011
DNAJB6 distal myopathy DNAJB6 AD Ruggieri et al., 2015 - Palmio et al., 2020
Rimmed vacuolar neuromyopathy HSPB8 AD Ghaoui et al., 2016
ANO5 distal muscular dystrophy ANO5 AR Bolduc et al., 2010
RYR1 mutated calf predominant distal myopathy RYR1 AD/AR Laughlin et al., 2017 - Jokela et al., 2019
Early-childhood onset distal myopathies
Early onset distal myopathy (Laing) MYH7 AD > AR Meredith et al., 2004
Early onset distal myopathies with nebulin defect NEB AR > AD Wallgren-Pettersson et al., 2007, Kiiski et al., 2019
Early onset ADSSL distal myopathy ADSSL AR Park et al., 2016
Early onset distal myopathy with KLHL9 mutations KLHL9 AD Cirak et al., 2010
Other myopathies and dystrophies with distal weakness
Distal myopathy with caveolin defect CAV3 AD Tateyama et al., 2002
DNM2 related distal myopathy DNM2 AD Bitoun et al., 2005

AD: autosomal dominant; AR: autosome recessive; DG: digenic

References

  • 1.Gowers WR. A lecture on myopathy and a distal form: delivered at the National Hospital for the Paralysed and Epileptic. Br Med J 1902;2:89-92. https://doi.org/10.1136/bmj.2.2167.89 10.1136/bmj.2.2167.89 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Liu J, Aoki M, Illa I, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 1998;20:31-6. https://doi.org/10.1038/1682 10.1038/1682 [DOI] [PubMed] [Google Scholar]
  • 3.Evila A, Arumilli M, Udd B, et al. Targeted next-generation sequencing assay for detection of mutations in primary myopathies. Neuromuscul Disord 2016;26:7-15. https://doi.org/10.1016/j.nmd.2015.10.003 10.1016/j.nmd.2015.10.003 [DOI] [PubMed] [Google Scholar]
  • 4.Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol 2018;5:1574-87. https://doi.org/10.1002/acn3.649 10.1002/acn3.649 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Savarese M, Di Fruscio G, Torella A, et al. The genetic basis of undiagnosed muscular dystrophies and myopathies: results from 504 patients. Neurology 2016;87:71-6. https://doi.org/10.1212/WNL.0000000000002800 10.1212/WNL.0000000000002800 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ankala A, da Silva C, Gualandi F, et al. A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield. Ann Neurol 2015;77:206-14. https://doi.org/10.1002/ana.24303 10.1002/ana.24303 [DOI] [PubMed] [Google Scholar]
  • 7.Ghaoui R, Cooper ST, Lek M, et al. Use of whole-exome sequencing for diagnosis of limb-girdle muscular dystrophy: outcomes and lessons learned. JAMA Neurol 2015;72:1424-32. https://doi.org/10.1001/jamaneurol.2015.2274 10.1001/jamaneurol.2015.2274 [DOI] [PubMed] [Google Scholar]
  • 8.Benarroch L, Bonne G, Rivier F, et al. The 2020 version of the gene table of neuromuscular disorders (nuclear genome). Neuromuscul Disord 2019;29:980-1018. https://doi.org/10.1016/j.nmd.2019.10.010 10.1016/j.nmd.2019.10.010 [DOI] [PubMed] [Google Scholar]
  • 9.Welander L. Myopathia distalis tarda hereditaria; 249 examined cases in 72 pedigrees. Acta Med Scand 1951(Suppl);265:1-124 (https://www.ncbi.nlm.nih.gov/pubmed/14894174. Published 1951/01/01). [PubMed] [Google Scholar]
  • 10.Hackman P, Sarparanta J, Lehtinen S, et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Ann Neurol 2013;73:500-9. https://doi.org/10.1002/ana.23831 10.1002/ana.23831 [DOI] [PubMed] [Google Scholar]
  • 11.Klar J, Sobol M, Melberg A, et al. Welander distal myopathy caused by an ancient founder mutation in TIA1 associated with perturbed splicing. Hum Mut 2013;34:572-7. https://doi.org/10.1002/humu.22282 10.1002/humu.22282 [DOI] [PubMed] [Google Scholar]
  • 12.Tian Q, Streuli M, Saito H, Schlossman SF, Anderson P. A polyadenylate binding protein localized to the granules of cytolytic lymphocytes induces DNA fragmentation in target cells. Cell 1991;67:629-39. https://doi.org/10.1016/0092-8674(91)90536-8 10.1016/0092-8674(91)90536-8 [DOI] [PubMed] [Google Scholar]
  • 13.Eisinger-Mathason TS, Andrade J, Groehler AL, et al. Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Mol Cell 2008;31:722-36. https://doi.org/10.1016/j.molcel.2008.06.025 10.1016/j.molcel.2008.06.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Forch P, Puig O, Kedersha N, et al. The apoptosis-promoting factor TIA-1 is a regulator of alternative pre-mRNA splicing. Mol Cell 2000;6:1089-98. https://doi.org/10.1016/s1097-2765(00)00107-6 10.1016/s1097-2765(00)00107-6 [DOI] [PubMed] [Google Scholar]
  • 15.Lee Y, Jonson PH, Sarparanta J, et al. TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. J Clin Invest 2018;128:1164-77. https://doi.org/10.1172/JCI97103 10.1172/JCI97103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Udd B, Hakamies L, Partanen J, et al. Tibial muscular dystrophy: late adult-onset distal myopathy in 66 Finnish patients. Arch Neurol 1993;50:604-8. https://doi.org/10.1001/archneur.1993.00540060044015 10.1001/archneur.1993.00540060044015 [DOI] [PubMed] [Google Scholar]
  • 17.Hackman P, Vihola A, Haravuori H, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002;71:492-500. https://doi.org/10.1086/342380 10.1086/342380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Pollazzon M, Suominen T, Penttila S, et al. The first Italian family with tibial muscular dystrophy caused by a novel titin mutation. J Neurol 2010;257:575-9. https://doi.org/10.1007/s00415-009-5372-3 10.1007/s00415-009-5372-3 [DOI] [PubMed] [Google Scholar]
  • 19.Van den Bergh PYK, Bouquiaux O, Verellen C, et al. Tibial muscular dystrophy in a Belgian family. Ann Neurol 2003;54:248-51. https://doi.org/10.1002/ana.10647 10.1002/ana.10647 [DOI] [PubMed] [Google Scholar]
  • 20.Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res 2001;89:1065-72. https://doi.org/10.1161/hh2301.100981 10.1161/hh2301.100981 [DOI] [PubMed] [Google Scholar]
  • 21.Charton K, Sarparanta J, Vihola A, et al. CAPN3-mediated processing of C-terminal titin replaced by pathological cleavage in titinopathy. Hum Mol Genet 2015;24:3718-31. https://doi.org/10.1093/hmg/ddv116 10.1093/hmg/ddv116 [DOI] [PubMed] [Google Scholar]
  • 22.Sarparanta J, Blandin G, Charton K, et al. Interactions with M-band titin and calpain 3 link myospryn (CMYA5) to tibial and limb-girdle muscular dystrophies. J Biol Che 2010;285:30304-15. https://doi.org/10.1074/jbc.M110.108720 10.1074/jbc.M110.108720 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Savarese M, Jonson PH, Huovinen S, et al. The complexity of titin splicing pattern in human adult skeletal muscles. Skelet Muscle 2018;8:11 https://doi.org/10.1186/s13395-018-0156-z 10.1186/s13395-018-0156-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Uapinyoying P, Goecks J, Knoblach SM, et al. A long-read RNA-seq approach to identify novel transcripts of very large genes. Genome Res 2020;30:885-97. https://doi.org/10.1101/gr.259903.119 10.1101/gr.259903.119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Savarese M, Sarparanta J, Vihola A, Udd B, Hackman P. Increasing role of titin mutations in neuromuscular disorders. J Neuromuscul Dis 2016;3:293-308. https://doi.org/10.3233/JND-160158 10.3233/JND-160158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Hackman P, Udd B, Bonnemann CG, et al. Titinopathy database C. 219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April-1 May 2016. Neuromuscul Disord 2017;27:396-407. https://doi.org/10.1016/j.nmd.2017.01.009 10.1016/j.nmd.2017.01.009 [DOI] [PubMed] [Google Scholar]
  • 27.Palmio J, Evila A, Chapon F, et al. Hereditary myopathy with early respiratory failure: occurrence in various populations. J Neurol Neurosurg Psychiatry 2014;85:345-53. https://doi.org/10.1136/jnnp-2013-304965 10.1136/jnnp-2013-304965 [DOI] [PubMed] [Google Scholar]
  • 28.Palmio J, Leonard-Louis S, Sacconi S, et al. Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. J Neurol 2019;266:680-90. https://doi.org/10.1007/s00415-019-09187-2 10.1007/s00415-019-09187-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Tasca G, Udd B. Hereditary myopathy with early respiratory failure (HMERF): still rare, but common enough. Neuromuscul Disord 2018;28:268-76. https://doi.org/10.1016/j.nmd.2017.12.002 10.1016/j.nmd.2017.12.002 [DOI] [PubMed] [Google Scholar]
  • 30.Savarese M, Vihola A, Oates EC, et al. Genotype-phenotype correlations in recessive titinopathies. Genet Med 2020;August 11 https://doi.org/10.1038/s41436-020-0914-2 10.1038/s41436-020-0914-2 [DOI] [PubMed] [Google Scholar]
  • 31.Oates EC, Jones KJ, Donkervoort S, et al. Congenital titinopathy: comprehensive characterization and pathogenic insights. Ann Neurol 2018;83:1105-24. https://doi.org/10.1002/ana.25241 10.1002/ana.25241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Herman DS, Lam L, Taylor MR, et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012;366:619-28. https://doi.org/10.1056/NEJMoa1110186 10.1056/NEJMoa1110186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Itoh-Satoh M, Hayashi T, Nishi H, et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun 2002;291:385-93. https://doi.org/10.1006/bbrc.2002.6448 10.1006/bbrc.2002.6448 [DOI] [PubMed] [Google Scholar]
  • 34.Feit H, Silbergleit A, Schneider LB, et al. Vocal cord and pharyngeal weakness with autosomal dominant distal myopathy: clinical description and gene localization to 5q31. Am J Hum Gen 1998;63:1732-42. https://doi.org/10.1086/302166 10.1086/302166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Senderek J, Garvey SM, Krieger M, et al. Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am J Hum Genet 2009;84:511-8. https://doi.org/10.1016/j.ajhg.2009.03.006 10.1016/j.ajhg.2009.03.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Muller TJ, Kraya T, Stoltenburg-Didinger G, et al. Phenotype of matrin-3-related distal myopathy in 16 German patients. Ann Neurol 2014;76:669-80. https://doi.org/10.1002/ana.24255 10.1002/ana.24255 [DOI] [PubMed] [Google Scholar]
  • 37.Barp A, Malfatti E, Metay C, et al. The first French case of MATR3-related distal myopathy: clinical, radiological and histopathological characterization. Rev Neurol (Paris) 2018;174:752-5. https://doi.org/10.1016/j.neurol.2017.08.004 10.1016/j.neurol.2017.08.004 [DOI] [PubMed] [Google Scholar]
  • 38.Kraya T, Schmidt B, Muller T, et al. Impairment of respiratory function in late-onset distal myopathy due to MATR3 Mutation. Muscle Nerve 2015;51:916-8. https://doi.org/10.1002/mus.24603 10.1002/mus.24603 [DOI] [PubMed] [Google Scholar]
  • 39.Mensch A, Kraya T, Koester F, et al. Whole-body muscle MRI of patients with MATR3-associated distal myopathy reveals a distinct pattern of muscular involvement and highlights the value of whole-body examination. J Neurol 2020;267:2408-20. https://doi.org/10.1007/s00415-020-09862-9 10.1007/s00415-020-09862-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Belgrader P, Dey R, Berezney R. Molecular cloning of matrin 3. A 125-kilodalton protein of the nuclear matrix contains an extensive acidic domain. J Biol Chem 1991;266:9893-9 ().https://www.ncbi.nlm.nih.gov/pubmed/2033075. Published 1991/05/25. [PubMed] [Google Scholar]
  • 41.Nakayasu H, Berezney R. Nuclear matrins: identification of the major nuclear matrix proteins. PNAS 1991;88:10312-6. https://doi.org/10.1073/pnas.88.22.10312 10.1073/pnas.88.22.10312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Johnson JO, Pioro EP, Boehringer A, et al. Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosc 2014;17:664-6. https://doi.org/10.1038/nn.3688 10.1038/nn.3688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Savarese M, Palmio J, Poza JJ, et al. Actininopathy: a new muscular dystrophy caused by ACTN2 dominant mutations. Ann Neurol 2019;85:899-906. https://doi.org/10.1002/ana.25470 10.1002/ana.25470 [DOI] [PubMed] [Google Scholar]
  • 44.Tiso N, Majetti M, Stanchi F, et al. Fine mapping and genomic structure of ACTN2, the human gene coding for the sarcomeric isoform of alpha-actinin-2, expressed in skeletal and cardiac muscle. Biochem Biophys Res Commun 1999;265:256-9. https://doi.org/10.1006/bbrc.1999.1661 10.1006/bbrc.1999.1661 [DOI] [PubMed] [Google Scholar]
  • 45.Young P, Ferguson C, Banuelos S, et al. Molecular structure of the sarcomeric Z-disk: two types of titin interactions lead to an asymmetrical sorting of alpha-actinin. EMBO J 1998;17:1614-24. https://doi.org/10.1093/emboj/17.6.1614 10.1093/emboj/17.6.1614 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Gupta V, Discenza M, Guyon JR, et al. alpha-Actinin-2 deficiency results in sarcomeric defects in zebrafish that cannot be rescued by alpha-actinin-3 revealing functional differences between sarcomeric isoforms. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2012;26:1892-908. https://doi.org/10.1096/fj.11-194548 10.1096/fj.11-194548 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ribeiro Ede A, Jr., Pinotsis N, Ghisleni A, et al. The structure and regulation of human muscle alpha-actinin. Cell 2014;159:1447-60. https://doi.org/10.1016/j.cell.2014.10.056 10.1016/j.cell.2014.10.056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Lornage X, Romero NB, Grosgogeat CA, et al. ACTN2 mutations cause “Multiple structured Core Disease” (MsCD). Acta Neuropathol 2019;137:501-19. https://doi.org/10.1007/s00401-019-01963-8 10.1007/s00401-019-01963-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Haywood NJ, Wolny M, Rogers B, et al. Hypertrophic cardiomyopathy mutations in the calponin-homology domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. Biochem J 2016;473:2485-93. https://doi.org/10.1042/BCJ20160421 10.1042/BCJ20160421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Mohapatra B, Jimenez S, Lin JH, et al. Mutations in the muscle LIM protein and alpha-actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol Genet Metab 2003;8:207-15. https://doi.org/10.1016/s1096-7192(03)00142-2 10.1016/s1096-7192(03)00142-2 [DOI] [PubMed] [Google Scholar]
  • 51.Chiu C, Bagnall RD, Ingles J, et al. Mutations in alpha-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis. J Am Coll Cardio 2010;55:1127-35. https://doi.org/10.1016/j.jacc.2009.11.016 10.1016/j.jacc.2009.11.016 [DOI] [PubMed] [Google Scholar]
  • 52.Girolami F, Iascone M, Tomberli B, et al. Novel alpha-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study. Circ Cardiovasc Genet 2014;7:741-50. https://doi.org/10.1161/CIRCGENETICS.113.000486 10.1161/CIRCGENETICS.113.000486 [DOI] [PubMed] [Google Scholar]
  • 53.Bagnall RD, Molloy LK, Kalman JM, et al. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. BMC Med Genet 2014;15:99 https://doi.org/10.1186/s12881-014-0099-0 10.1186/s12881-014-0099-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Edstrom L, Thornell LE, Eriksson A. A new type of hereditary distal myopathy with characteristic sarcoplasmic bodies and intermediate (skeletin) filaments. J Neurol Sci 1980;47:171-90. https://doi.org/10.1016/0022-510x(80)90002-7 10.1016/0022-510x(80)90002-7 [DOI] [PubMed] [Google Scholar]
  • 55.Olive M, Engvall M, Ravenscroft G, et al. Myoglobinopathy is an adult-onset autosomal dominant myopathy with characteristic sarcoplasmic inclusions. Nat Commun 2019;10:1396 https://doi.org/10.1038/s41467-019-09111-2 10.1038/s41467-019-09111-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Durmus H, Laval SH, Deymeer F, et al. Oculopharyngodistal myopathy is a distinct entity: Clinical and genetic features of 47 patients. Neurology 2011;76:227-35. https://doi.org/10.1212/WNL.0b013e318207b043 10.1212/WNL.0b013e318207b043 [DOI] [PubMed] [Google Scholar]
  • 57.Lu H, Luan X, Yuan Y, et al. The clinical and myopathological features of oculopharyngodistal myopathy in a Chinese family. Neuropathology 2008;28:599-603. https://doi.org/10.1111/j.1440-1789.2008.00924.x 10.1111/j.1440-1789.2008.00924.x [DOI] [PubMed] [Google Scholar]
  • 58.Ishiura H, Shibata S, Yoshimura J, et al. Noncoding CGG repeat expansions in neuronal intranuclear inclusion disease, oculopharyngodistal myopathy and an overlapping disease. Nat Genet 2019;51:1222-32. https://doi.org/10.1038/s41588-019-0458-z 10.1038/s41588-019-0458-z [DOI] [PubMed] [Google Scholar]
  • 59.Saito R, Shimizu H, Miura T, et al. Oculopharyngodistal myopathy with coexisting histology of systemic neuronal intranuclear inclusion disease: clinicopathologic features of an autopsied patient harboring CGG repeat expansions in LRP12. Acta Neuropathol Commun. 2020;8:75 https://doi.org/10.1186/s40478-020-00945-2 10.1186/s40478-020-00945-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Sone J, Mitsuhashi S, Fujita A, et al. Long-read sequencing identifies GGC repeat expansions in NOTCH2NLC associated with neuronal intranuclear inclusion disease. Nat Genet 2019;51:1215-21. https://doi.org/10.1038/s41588-019-0459-y 10.1038/s41588-019-0459-y [DOI] [PubMed] [Google Scholar]
  • 61.Deng J, Yu J, Li P, et al. Expansion of GGC repeat in GIPC1 is associated with oculopharyngodistal myopathy. Am J Hum Genet 2020;106:793-804. https://doi.org/10.1016/j.ajhg.2020.04.011 10.1016/j.ajhg.2020.04.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Di Blasi C, Moghadaszadeh B, Ciano C, et al. Abnormal lysosomal and ubiquitin-proteasome pathways in 19p13.3 distal myopathy. Ann Neurol 2004;56:133-8. https://doi.org/10.1002/ana.20158 10.1002/ana.20158 [DOI] [PubMed] [Google Scholar]
  • 63.Ruggieri A, Naumenko S, Smith MA, et al. Multiomic elucidation of a coding 99-mer repeat-expansion skeletal muscle disease. Acta Neuropathol 2020;140:231-5. https://doi.org/10.1007/s00401-020-02164-4 10.1007/s00401-020-02164-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pourteymour S, Lee S, Langleite TM, et al. Perilipin 4 in human skeletal muscle: localization and effect of physical activity. Physiol Rep 2015;3 https://doi.org/10.14814/phy2.12481 10.14814/phy2.12481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Palmio J, Sandell S, Suominen T, et al. Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. Neuromuscul Disord 2011;21:551-5. https://doi.org/10.1016/j.nmd.2011.05.008 10.1016/j.nmd.2011.05.008 [DOI] [PubMed] [Google Scholar]
  • 66.Ikenaga C, Findlay AR, Seiffert M, et al. Phenotypic diversity in an international Cure VCP Disease registry. Orphanet J Rare Dis 2020;15:267 https://doi.org/10.1186/s13023-020-01551-0 10.1186/s13023-020-01551-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Guo X, Zhao Z, Shen H, et al. VCP myopathy: A family with unusual clinical manifestations. Muscle Nerve 2019;59:365-9. https://doi.org/10.1002/mus.26389 10.1002/mus.26389 [DOI] [PubMed] [Google Scholar]
  • 68.Al-Tahan S, Al-Obeidi E, Yoshioka H, et al. Novel valosin-containing protein mutations associated with multisystem proteinopathy. Neuromuscul Disor 2018;28:91-501. https://doi.org/10.1016/j.nmd.2018.04.007 10.1016/j.nmd.2018.04.007 [DOI] [PubMed] [Google Scholar]
  • 69.Boland-Freitas R, Graham J, Davis M, et al. Late-onset distal myopathy of the upper limbs due to P.Ile151Val mutation in the valosin-containing protein. Muscle Nerve 2016;54:165-6. https://doi.org/10.1002/mus.25073 10.1002/mus.25073 [DOI] [PubMed] [Google Scholar]
  • 70.Kazamel M, Sorenson EJ, McEvoy KM, et al. Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve 2016;54:94-9. https://doi.org/10.1002/mus.24980 10.1002/mus.24980 [DOI] [PubMed] [Google Scholar]
  • 71.Liewluck T, Milone M, Mauermann ML, et al. A novel VCP mutation underlies scapuloperoneal muscular dystrophy and dropped head syndrome featuring lobulated fibers. Muscle Nerve 2014;50:295-9. https://doi.org/10.1002/mus.24290 10.1002/mus.24290 [DOI] [PubMed] [Google Scholar]
  • 72.Shi Z, Hayashi YK, Mitsuhashi S, et al. Characterization of the Asian myopathy patients with VCP mutations. Eur J Neurol 2012;19:501-9. https://doi.org/10.1111/j.1468-1331.2011.03575.x 10.1111/j.1468-1331.2011.03575.x [DOI] [PubMed] [Google Scholar]
  • 73.Papadopoulos C, Malfatti E, Anagnostou E, et al. Valosin-containing protein-related myopathy and Meige syndrome: Just a coincidence or not? Muscle Nerve 2019;60:e43-5. https://doi.org/10.1002/mus.26704 10.1002/mus.26704 [DOI] [PubMed] [Google Scholar]
  • 74.Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nature Genetics 2004;36:377-81. https://doi.org/10.1038/ng1332 10.1038/ng1332 [DOI] [PubMed] [Google Scholar]
  • 75.Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in familial VCP myopathy associated with paget disease of bone and frontotemporal dementia. Am J Med Genet, Part A. 2008;146:745-57. https://doi.org/10.1002/ajmg.a.31862 10.1002/ajmg.a.31862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Stojkovic T, Hammouda EH, Richard P, et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget’s disease of bone and frontotemporal dementia. Neuromuscul Disord 2009;19:316-23. https://doi.org/10.1016/j.nmd.2009.02.012 10.1016/j.nmd.2009.02.012 [DOI] [PubMed] [Google Scholar]
  • 77.Olivé M, Goldfarb LG, Shatunov A, et al. Refining the clinical and myopathological phenotype. Brain 2005;128:2315-26. https://doi.org/10.1093/brain/awh576 10.1093/brain/awh576 [DOI] [PubMed] [Google Scholar]
  • 78.Pénisson-Besnier I, Talvinen K, Dumez C, et al. Myotilinopathy in a family with late onset myopathy. Neuromuscular Disord 2006;16:427-31. https://doi.org/10.1016/j.nmd.2006.04.009 10.1016/j.nmd.2006.04.009 [DOI] [PubMed] [Google Scholar]
  • 79.Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. Neurology 2004;62:1363-71. https://doi.org/10.1212/01.wnl.0000123576.74801.75 10.1212/01.wnl.0000123576.74801.75 [DOI] [PubMed] [Google Scholar]
  • 80.Fischer D, Clemen CS, Olive M, et al. Different early pathogenesis in myotilinopathy compared to primary desminopathy. Neuromuscul Disord 2006;16:361-7. https://doi.org/10.1016/j.nmd.2006.03.007 10.1016/j.nmd.2006.03.007 [DOI] [PubMed] [Google Scholar]
  • 81.Maerkens A, Olive M, Schreiner A, et al. New insights into the protein aggregation pathology in myotilinopathy by combined proteomic and immunolocalization analyses. Acta Neuropathol Commun 2016;4:8 https://doi.org/10.1186/s40478-016-0280-0 10.1186/s40478-016-0280-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Fischer D, Kley RA, Strach K, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology 2008;71:758-65. https://doi.org/10.1212/01.wnl.0000324927.28817.9b 10.1212/01.wnl.0000324927.28817.9b [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Bugiardini E, Morrow JM, Shah S, et al. The diagnostic value of MRI pattern recognition in distal myopathies. Front Neurol 2018;9:456.https://doi.org/10.3389/fneur.2018.00456 10.3389/fneur.2018.00456 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Salmikangas P, van der Ven PF, Lalowski M, et al. Myotilin, the limb-girdle muscular dystrophy 1A (LGMD1A) protein, cross-links actin filaments and controls sarcomere assembly. Hum Mol Genet 2003;12:189-203. https://doi.org/10.1093/hmg/ddg020 10.1093/hmg/ddg020 [DOI] [PubMed] [Google Scholar]
  • 85.Hauser MA, Horrigan SK, Salmikangas P, et al. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum Mol Genet 2000;9:2141-7. https://doi.org/10.1093/hmg/9.14.2141 10.1093/hmg/9.14.2141 [DOI] [PubMed] [Google Scholar]
  • 86.Hauser MA, Conde CB, Kowaljow V, et al. myotilin Mutation found in second pedigree with LGMD1A. Am J Hum Genet 2002;71:1428-32. https://doi.org/10.1086/344532 10.1086/344532 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Rudolf G, Suominen T, Penttila S, et al. Homozygosity of the dominant myotilin c.179C>T (p.Ser60Phe) mutation causes a more severe and proximal muscular dystrophy. J Neuromuscul Disord 2016;3:275-81. https://doi.org/10.3233/JND-150143 10.3233/JND-150143 [DOI] [PubMed] [Google Scholar]
  • 88.Schessl J, Bach E, Rost S, et al. Novel recessive myotilin mutation causes severe myofibrillar myopathy. Neurogenetics 2014;15:151-6. https://doi.org/10.1007/s10048-014-0410-4 10.1007/s10048-014-0410-4 [DOI] [PubMed] [Google Scholar]
  • 89.Foroud T, Pankratz N, Batchman AP, et al. A mutation in myotilin causes spheroid body myopathy. Neurology 2005;65:1936-40. https://doi.org/10.1212/01.wnl.0000188872.28149.9a 10.1212/01.wnl.0000188872.28149.9a [DOI] [PubMed] [Google Scholar]
  • 90.Goebel HH, Muller J, Gillen HW, et al. Autosomal dominant “spheroid body myopathy”. Muscle Nerve 1978;1:14-26. https://doi.org/10.1002/mus.880010104 10.1002/mus.880010104 [DOI] [PubMed] [Google Scholar]
  • 91.Griggs R, Vihola A, Hackman P, et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain 2007;130(Pt 6):1477-84. https://doi.org/10.1093/brain/awm006 10.1093/brain/awm006 [DOI] [PubMed] [Google Scholar]
  • 92.Newby R, Jamieson S, Udd B, et al. When myopathy breaks the rules: a late-onset distal presentation. BMJ Case Rep 2015;2015 https://doi.org/10.1136/bcr-2015-209436 10.1136/bcr-2015-209436 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Zheng J, Chen S, Chen Y, et al. A novel mutation in the PDZ-like motif of ZASP causes distal ZASP-related myofibrillar myopathy. Neuropathology 2017;37:45-51. https://doi.org/10.1111/neup.12328 10.1111/neup.12328 [DOI] [PubMed] [Google Scholar]
  • 94.Strach K, Reimann J, Thomas D, et al. ZASPopathy with childhood-onset distal myopathy. J Neurol 2012;259:1494-6. https://doi.org/10.1007/s00415-012-6543-1 10.1007/s00415-012-6543-1 [DOI] [PubMed] [Google Scholar]
  • 95.Behin A, Salort-Campana E, Wahbi K, et al. Myofibrillar myopathies: state of the art, present and future challenges. Rev Neurol (Paris) 2015;171:715-29. https://doi.org/10.1016/j.neurol.2015.06.002 10.1016/j.neurol.2015.06.002 [DOI] [PubMed] [Google Scholar]
  • 96.Claeys KG, Fardeau M, Schröder R, et al. Electron microscopy in myofibrillar myopathies reveals clues to the mutated gene. Neuromuscul Disord 2008;18:656-66. https://doi.org/10.1016/j.nmd.2008.06.367 10.1016/j.nmd.2008.06.367 [DOI] [PubMed] [Google Scholar]
  • 97.Lin X, Ruiz J, Bajraktari I, et al. Z-disc-associated, alternatively spliced, PDZ motif-containing protein (ZASP) mutations in the actin-binding domain cause disruption of skeletal muscle actin filaments in myofibrillar myopathy. J Biol Chem 2014;289:13615-26. https://doi.org/10.1074/jbc.M114.550418 10.1074/jbc.M114.550418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Martinelli VC, Kyle WB, Kojic S, et al. ZASP interacts with the mechanosensing protein Ankrd2 and p53 in the signalling network of striated muscle. PLoS One 2014;9:e92259 https://doi.org/10.1371/journal.pone.0092259 10.1371/journal.pone.0092259 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 99.Vatta M, Mohapatra B, Jimenez S, et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol 2003;42:2014-27. https://doi.org/10.1016/j.jacc.2003.10.021 10.1016/j.jacc.2003.10.021 [DOI] [PubMed] [Google Scholar]
  • 100.Xing Y, Ichida F, Matsuoka T, et al. Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Mol Genet Metab 2006;88:71-7. https://doi.org/10.1016/j.ymgme.2005.11.009 10.1016/j.ymgme.2005.11.009 [DOI] [PubMed] [Google Scholar]
  • 101.Milhorat AT, Wolff HG. Studies in diseases of muscle: XIII. Progressive muscular dystrophy of atrophic distal type; report on a family; report of autopsy. Arch Neurol Psychiatry 1943;49:655-64.10.1001/archneurpsyc.1943.02290170025002 10.1001/archneurpsyc.1943.02290170025002 [DOI] [Google Scholar]
  • 102.Van Spaendonck-Zwarts KY, Van Hessem L, Jongbloed JDH, et al. Desmin-related myopathy. Clin Genet 2011;80:354-66. https://doi.org/10.1111/j.1399-0004.2010.01512.x 10.1111/j.1399-0004.2010.01512.x [DOI] [PubMed] [Google Scholar]
  • 103.Goldfarb LG, Park KY, Cervenákova L, et al. Missense mutations in desmin associated with familial cardiac and skeletal myopathy. Nature Genet 1998;19:402-3. https://doi.org/10.1038/1300 10.1038/1300 [DOI] [PubMed] [Google Scholar]
  • 104.Kouloumenta A, Mavroidis M, Capetanaki Y. Proper perinuclear localization of the TRIM-like protein myospryn requires its binding partner desmin. J Biol Chem 2007;28:35211-21. https://doi.org/10.1074/jbc.M704733200 10.1074/jbc.M704733200 [DOI] [PubMed] [Google Scholar]
  • 105.Kedia N, Arhzaouy K, Pittman SK, et al. Desmin forms toxic, seeding-competent amyloid aggregates that persist in muscle fibers. PNAS 2019;116:16835-40. https://doi.org/10.1073/pnas.1908263116 10.1073/pnas.1908263116 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Palmio J, Penttilä S, Huovinen S, Haapasalo H, Udd B. An unusual phenotype of late-onset desminopathy. Neuromuscul Disord 2013;23:922-3. https://doi.org/10.1016/j.nmd.2013.06.374 10.1016/j.nmd.2013.06.374 [DOI] [PubMed] [Google Scholar]
  • 107.Riley LG, Waddell LB, Ghaoui R, et al. Recessive DES cardio/myopathy without myofibrillar aggregates: intronic splice variant silences one allele leaving only missense L190P-desmin. Eur J Hum Genet 2019;27:1267-73. https://doi.org/10.1038/s41431-019-0393-6 10.1038/s41431-019-0393-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Investig 2009;119:1806-13. https://doi.org/10.1172/JCI38027 10.1172/JCI38027 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Goldfarb LG, Olivé M, Vicart P, et al. Intermediate filament diseases: desminopathy. Adv Exp Med Biol 2008;642:131-64. https://doi.org/10.1007/978-0-387-84847-1_11 10.1007/978-0-387-84847-1_11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Walter M, Reichlich P, Hübner A. Identification of a desmin gene mutation in scapuloperoneal syndrome type Kaeser. Neuromuscul Disord 2006;16:708-9. [Google Scholar]
  • 111.Li D, Tapscoft T, Gonzalez O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999;100:461-4. https://doi.org/10.1161/01.cir.100.5.461 10.1161/01.cir.100.5.461 [DOI] [PubMed] [Google Scholar]
  • 112.Taylor MR, Slavov D, Ku L, et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 2007;115:1244-51. https://doi.org/10.1161/circulationaha.106.646778 10.1161/circulationaha.106.646778 [DOI] [PubMed] [Google Scholar]
  • 113.Vicart P, Caron A, Guicheney P, et al. A missense mutation in the αb-crystallin chaperone gene causes a desmin-related myopathy. Nature Genet 1998;20:92-5. https://doi.org/10.1038/1765 10.1038/1765 [DOI] [PubMed] [Google Scholar]
  • 114.Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann Neurol 2003;54:804-10. https://doi.org/10.1002/ana.10767 10.1002/ana.10767 [DOI] [PubMed] [Google Scholar]
  • 115.Reilich P, Schoser B, Schramm N, et al. The p.G154S mutation of the alpha-B crystallin gene (CRYAB) causes late-onset distal myopathy. Neuromuscul Disord 2010;20(4):255-9. https://doi.org/10.1016/j.nmd.2010.01.012 10.1016/j.nmd.2010.01.012 [DOI] [PubMed] [Google Scholar]
  • 116.Sacconi S, Feasson L, Antoine JC, et al. A novel CRYAB mutation resulting in multisystemic disease. Neuromuscul Disord 2012;22:66-72. https://doi.org/10.1016/j.nmd.2011.07.004 10.1016/j.nmd.2011.07.004 [DOI] [PubMed] [Google Scholar]
  • 117.Bortolani S, Fattori F, Monforte M, et al. Peculiar muscle imaging findings in a patient with alphaB-crystallinopathy and axial myopathy. J Neurol Sci 2020;416:116999 https://doi.org/10.1016/j.jns.2020.116999 10.1016/j.jns.2020.116999 [DOI] [PubMed] [Google Scholar]
  • 118.Carvalho AAS, Lacene E, Brochier G, et al. Genetic mutations and demographic, clinical, and morphological aspects of myofibrillar myopathy in a French cohort. Genet Test Mol Biomarkers 2018;22:374-83. https://doi.org/10.1089/gtmb.2018.0004 10.1089/gtmb.2018.0004 [DOI] [PubMed] [Google Scholar]
  • 119.Sarparanta J, Jonson PH, Kawan S, et al. Neuromuscular diseases due to chaperone mutations: a review and some new results. Int J Mol Sc 2020;21 https://doi.org/10.3390/ijms21041409 10.3390/ijms21041409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.D’Agostino M, Scerra G, Cannata Serio M, et al. Unconventional secretion of alpha-crystallin B requires the autophagic pathway and is controlled by phosphorylation of its serine 59 residue. Sci Rep 2019;9:16892 https://doi.org/10.1038/s41598-019-53226-x 10.1038/s41598-019-53226-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Ciano M, Allocca S, Ciardulli MC, et al. Differential phosphorylation-based regulation of alphaB-crystallin chaperone activity for multipass transmembrane proteins. Biochem Biophys Res Commun 2016;479:325-30. https://doi.org/10.1016/j.bbrc.2016.09.071 10.1016/j.bbrc.2016.09.071 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.D’Agostino M, Lemma V, Chesi G, et al. The cytosolic chaperone alpha-crystallin B rescues folding and compartmentalization of misfolded multispan transmembrane proteins. J Cell Sci 2013;126(Pt 18):4160-72. https://doi.org/10.1242/jcs.125443 10.1242/jcs.125443 [DOI] [PubMed] [Google Scholar]
  • 123.Del Bigio MR, Chudley AE, Sarnat HB, et al. Infantile muscular dystrophy in Canadian aboriginals is an alphaB-crystallinopathy. Ann Neurol 2011;69:866-71. https://doi.org/10.1002/ana.22331 10.1002/ana.22331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Inagaki N, Hayashi T, Arimura T, et al. Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem Biophys Res Commu 2006;342:379-86. https://doi.org/10.1016/j.bbrc.2006.01.154 10.1016/j.bbrc.2006.01.154 [DOI] [PubMed] [Google Scholar]
  • 125.Berry V, Francis P, Reddy MA, et al. Alpha-B crystallin gene (CRYAB) mutation causes dominant congenital posterior polar cataract in humans. Am J Hum Genet 2001;69:1141-5. https://doi.org/10.1086/324158 10.1086/324158 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Ma K, Luo D, Tian T, et al. A novel homozygous initiation codon variant associated with infantile alpha-Bcrystallinopathy in a Chinese family. Mol Genet Genomic Med 2019;7:e825 https://doi.org/10.1002/mgg3.825 10.1002/mgg3.825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Marcos AT, Amoros D, Munoz-Cabello B, et al. A novel dominant mutation in CRYAB gene leading to a severe phenotype with childhood onset. Mol Genet Genomic Med 2020;8:e1290 https://doi.org/10.1002/mgg3.1290 10.1002/mgg3.1290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.Miyoshi K, Tada Y, Iwasa M. Autosomal recessive distal myopathy observed characteristically in Japan. Jpn J Hum Genet 1975;20:62-63. [PubMed] [Google Scholar]
  • 129.Bansal D, Campbell KP. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends in Cell Biology 2004;14:206-13. https://doi.org/10.1016/j.tcb.2004.03.001 10.1016/j.tcb.2004.03.001 [DOI] [PubMed] [Google Scholar]
  • 130.Glover L, Brown RH., Jr. Dysferlin in membrane trafficking and patch repair. Traffic 2007;8:785-94. https://doi.org/10.1111/j.1600-0854.2007.00573.x 10.1111/j.1600-0854.2007.00573.x [DOI] [PubMed] [Google Scholar]
  • 131.Klinge L, Harris J, Sewry C, et al. Dysferlin associates with the developing T-tubule system in rodent and human skeletal muscle. Muscle Nerve 2010;41:166-73. https://doi.org/10.1002/mus.21166 10.1002/mus.21166 [DOI] [PubMed] [Google Scholar]
  • 132.Cacciottolo M, Numitone G, Aurino S, et al. Muscular dystrophy with marked dysferlin deficiency is consistently caused by primary dysferlin gene mutations. Eur J Hum Genet 2011;19:974-80. https://doi.org/10.1038/ejhg.2011.70 10.1038/ejhg.2011.70 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Cox D, Henderson M, Straub V, et al. A simple and rapid immunoassay predicts dysferlinopathies in peripheral blood film. Neuromuscul Disord 2019;29:874-80. https://doi.org/10.1016/j.nmd.2019.09.008 10.1016/j.nmd.2019.09.008 [DOI] [PubMed] [Google Scholar]
  • 134.Magri F, Nigro V, Angelini C, et al. The Italian limb girdle muscular dystrophy registry: Relative frequency, clinical features, and differential diagnosis. Muscle Nerve 2017;55:55-68. https://doi.org/10.1002/mus.25192 10.1002/mus.25192 [DOI] [PubMed] [Google Scholar]
  • 135.Wang L, Zhang VW, Li S, et al. The clinical spectrum and genetic variability of limb-girdle muscular dystrophy in a cohort of Chinese patients. Orphanet J Rare Dis 2018;13:133 https://doi.org/10.1186/s13023-018-0859-6 10.1186/s13023-018-0859-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 136.Izumi R, Takahashi T, Suzuki N, et al. The genetic profile of dysferlinopathy in a cohort of 209 cases: genotype-phenotype relationship and a hotspot on the inner DysF domain. Hum Mutat 2020;41:1540-54. https://doi.org/10.1002/humu.24036 10.1002/humu.24036 [DOI] [PubMed] [Google Scholar]
  • 137.Fatehi F, Nafissi S, Urtizberea JA, et al. Dysferlinopathy in Iran: clinical and genetic report. J Neurol Sci 2015;359:256-9. https://doi.org/10.1016/j.jns.2015.11.009 10.1016/j.jns.2015.11.009 [DOI] [PubMed] [Google Scholar]
  • 138.Bushby KM. The limb-girdle muscular dystrophies-multiple genes, multiple mechanisms. Hum Mol Genet 1999;8:1875-82. https://doi.org/10.1093/hmg/8.10.1875 10.1093/hmg/8.10.1875 [DOI] [PubMed] [Google Scholar]
  • 139.Nigro V, Savarese M. Genetic basis of limb-girdle muscular dystrophies: the 2014 update. Acta Myol 2014;33:1-12. PMID . [PMC free article] [PubMed] [Google Scholar]
  • 140.Klinge L, Dean AF, Kress W, et al. Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord 2008;18:288-90. https://doi.org/10.1016/j.nmd.2008.01.004 10.1016/j.nmd.2008.01.004 [DOI] [PubMed] [Google Scholar]
  • 141.Evila A, Palmio J, Vihola A, et al. Targeted next-generation sequencing reveals novel TTN mutations causing recessive distal titinopathy. Mol Neurobiol 2017;54:7212-23. https://doi.org/10.1007/s12035-016-0242-3 10.1007/s12035-016-0242-3 [DOI] [PubMed] [Google Scholar]
  • 142.Evila A, Vihola A, Sarparanta J, et al. Atypical phenotypes in titinopathies explained by second titin mutations. Ann Neurol 2014;75:230-40. https://doi.org/10.1002/ana.24102 10.1002/ana.24102 [DOI] [PubMed] [Google Scholar]
  • 143.Hackman P, Marchand S, Sarparanta J, et al. Truncating mutations in C-terminal titin may cause more severe tibial muscular dystrophy (TMD). Neuromuscul Disord 2008;18:922-8. https://doi.org/10.1016/j.nmd.2008.07.010 10.1016/j.nmd.2008.07.010 [DOI] [PubMed] [Google Scholar]
  • 144.Savarese M, Maggi L, Vihola A, et al. Interpreting genetic variants in titin in patients with muscle disorders. JAMA Neurol 2018;75:557-65. https://doi.org/10.1001/jamaneurol.2017.4899 10.1001/jamaneurol.2017.4899 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145.Penisson-Besnier I, Hackman P, Suominen T, et al. Myopathies caused by homozygous titin mutations: limb-girdle muscular dystrophy 2J and variations of phenotype. J Neurol Neurosurg Psychiatry 2010;81:1200-2. https://doi.org/10.1136/jnnp.2009.178434 10.1136/jnnp.2009.178434 [DOI] [PubMed] [Google Scholar]
  • 146.Savarese M, Johari M, Johnson K, et al. Improved criteria for the classification of titin variants in inherited skeletal myopathies. J Neuromuscul Dis 2020;7:153-66. https://doi.org/10.3233/JND-190423 10.3233/JND-190423 [DOI] [PubMed] [Google Scholar]
  • 147.Savarese M, Valipakka S, Johari M, et al. Is gene-size an issue for the diagnosis of skeletal muscle disorders? J Neuromuscul Dis 2020;7:203-16. https://doi.org/10.3233/JND-190459 10.3233/JND-190459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148.Välipakka S, Savarese M, Johari M, et al. Copy number variation analysis increases the diagnostic yield in muscle diseases. Neurol Genet 2017;3 https://doi.org/10.1212/nxg.0000000000000204 10.1212/nxg.0000000000000204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149.Sagath L, Lehtokari VL, Valipakka S, et al. An extended targeted copy number variation detection array including 187 genes for the diagnostics of neuromuscular disorders. J Neuromuscul Dis 2018;5:307-14. https://doi.org/10.3233/JND-170298 10.3233/JND-170298 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150.Valipakka S, Savarese M, Sagath L, et al. Improving copy number variant detection from sequencing data with a combination of programs and a predictive model. J Mol Diagn 2020;22:40-9. https://doi.org/10.1016/j.jmoldx.2019.08.009 10.1016/j.jmoldx.2019.08.009 [DOI] [PubMed] [Google Scholar]
  • 151.Bryen SJ, Ewans LJ, Pinner J, et al. Recurrent TTN metatranscript-only c.39974-11T>G splice variant associated with autosomal recessive arthrogryposis multiplex congenita and myopathy. Hum Mutat 2020;41:403-11. https://doi.org/10.1002/humu.23938 10.1002/humu.23938 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 152.Savarese M, Qureshi T, Torella A, et al. Identification and characterization of splicing defects by single-molecule real-time sequencing technology (PacBio). J Neuromuscul Dis 2020;7:477-81. https://doi.org/10.3233/JND-200523 10.3233/JND-200523 [DOI] [PubMed] [Google Scholar]
  • 153.Nonaka I, Sunohara N, Ishiura S, et al. Familial distal myopathy with rimmed vacuole and lamellar (myeloid) body formation. J Neurol Sci 1981;51:141-5. https://doi.org/10.1016/0022-510X(81)90067-8 10.1016/0022-510X(81)90067-8 [DOI] [PubMed] [Google Scholar]
  • 154.Argov Z, Yarom R. “Rimmed vacuole myopathy” sparing the quadriceps. A unique disorder in iranian jews. J Neurol Sci 1984;64:33-43. https://doi.org/10.1016/0022-510X(84)90053-4 10.1016/0022-510X(84)90053-4 [DOI] [PubMed] [Google Scholar]
  • 155.Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-7. https://doi.org/10.1038/ng718 10.1038/ng718 [DOI] [PubMed] [Google Scholar]
  • 156.Keppler OT, Hinderlich S, Langner J, et al. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 1999;284:1372-6. https://doi.org/10.1126/science.284.5418.1372 10.1126/science.284.5418.1372 [DOI] [PubMed] [Google Scholar]
  • 157.Sela I, Goss V, Becker-Cohen M, et al. The glycomic sialylation profile of GNE Myopathy muscle cells does not point to consistent hyposialylation of individual glycoconjugates. Neuromuscul Disord 2020;30:621-30. https://doi.org/10.1016/j.nmd.2020.05.008 10.1016/j.nmd.2020.05.008 [DOI] [PubMed] [Google Scholar]
  • 158.Chen Y, Xi J, Zhu W, et al. GNE myopathy in Chinese population: hotspot and novel mutations. J Hum Genet 2019;64:11-6. https://doi.org/10.1038/s10038-018-0525-9 10.1038/s10038-018-0525-9 [DOI] [PubMed] [Google Scholar]
  • 159.Bhattacharya S, Khadilkar SV, Nalini A, et al. Mutation Spectrum of GNE Myopathy in the Indian Sub-Continent. J Neuromuscul Dis 2018;5:85-92. https://doi.org/10.3233/JND-170270 10.3233/JND-170270 [DOI] [PubMed] [Google Scholar]
  • 160.Papadimas GK, Evila A, Papadopoulos C, et al. GNE-myopathy in a Greek Romani family with unusual calf phenotype and protein aggregation pathology. J Neuromuscul Dis 2016;3:283-8. https://doi.org/10.3233/JND-160154 10.3233/JND-160154 [DOI] [PubMed] [Google Scholar]
  • 161.Alrohaif H, Pogoryelova O, Al-Ajmi A, et al. GNE myopathy in the bedouin population of Kuwait: genetics, prevalence, and clinical description. Muscle Nerve 2018;58:700-7. https://doi.org/10.1002/mus.26337 10.1002/mus.26337 [DOI] [PubMed] [Google Scholar]
  • 162.Khadilkar SV, Nallamilli BRR, Bhutada A, et al. A report on GNE myopathy: individuals of Rajasthan ancestry share the Roma gene. J Neurol Sci 2017;375:239-40. https://doi.org/10.1016/j.jns.2017.02.005 10.1016/j.jns.2017.02.005 [DOI] [PubMed] [Google Scholar]
  • 163.Pogoryelova O, Urtizberea JA, Argov Z, et al. 237th ENMC International Workshop: GNE myopathy – current and future research Hoofddorp, The Netherlands, 14-16 September 2018. Neuromuscul Disord 2019;29:401-10. https://doi.org/10.1016/j.nmd.2019.02.010 10.1016/j.nmd.2019.02.010 [DOI] [PubMed] [Google Scholar]
  • 164.Chakravorty S, Berger K, Arafat D, et al. Clinical utility of RNA sequencing to resolve unusual GNE myopathy with a novel promoter deletion. Muscle Nerve 2019;60:98-103. https://doi.org/10.1002/mus.26486 10.1002/mus.26486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165.Garland J, Stephen J, Class B, et al. Identification of an Alu element-mediated deletion in the promoter region of GNE in siblings with GNE myopathy. Mol Genet Genomic Med 2017;5:410-7. https://doi.org/10.1002/mgg3.300 10.1002/mgg3.300 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166.Miao J, Wei XJ, Wang X, et al. A case report: identification of a novel exon 1 deletion mutation in the GNE gene in a Chinese patient with GNE myopathy. Medicine (Baltimore) 2020;99:e22663.10.1097/MD.0000000000022663 10.1097/MD.0000000000022663 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167.Zhu W, Eto M, Mitsuhashi S, et al. GNE myopathy caused by a synonymous mutation leading to aberrant mRNA splicing. Neuromuscul Disord 2018;28:154-7. https://doi.org/10.1016/j.nmd.2017.11.003 10.1016/j.nmd.2017.11.003 [DOI] [PubMed] [Google Scholar]
  • 168.Pogoryelova O, Cammish P, Mansbach H, et al. Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy Disease Monitoring Program, registry portion. Neuromuscul Disord 2018;28:158-68. https://doi.org/10.1016/j.nmd.2017.11.001 10.1016/j.nmd.2017.11.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169.Pogoryelova O, Wilson IJ, Mansbach H, et al. GNE genotype explains 20% of phenotypic variability in GNE myopathy. Neurol Genet 2019;5:e308 https://doi.org/10.1212/NXG.0000000000000308 10.1212/NXG.0000000000000308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170.Soule T, Phan C, White C, et al. GNE myopathy with novel mutations and pronounced paraspinal muscle atrophy. Front Neurol 2018;9:942 https://doi.org/10.3389/fneur.2018.00942 10.3389/fneur.2018.00942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Seppala R, Lehto VP, Gahl WA. Mutations in the human UDP-N-acetylglucosamine 2-epimerase gene define the disease sialuria and the allosteric site of the enzyme. Am J Hum Genet 1999;64:1563-9. https://doi.org/10.1086/302411 10.1086/302411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172.Williams DR, Reardon K, Roberts L, et al. A new dominant distal myopathy affecting posterior leg and anterior upper limb muscles. Neurology 2005;64:1245-54. https://doi.org/10.1212/01.WNL.0000156524.95261.B9 10.1212/01.WNL.0000156524.95261.B9 [DOI] [PubMed] [Google Scholar]
  • 173.Duff RM, Tay V, Hackman P, et al. Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. Am J Hum Genet 2011;88:729-40. https://doi.org/10.1016/j.ajhg.2011.04.021 10.1016/j.ajhg.2011.04.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174.Mao Z, Nakamura F. Structure and function of filamin C in the muscle Z-disc. Int J Mol Sc 2020;21 https://doi.org/10.3390/ijms21082696 10.3390/ijms21082696 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Gonzalez-Morales N, Holenka TK, Schock F. Filamin actin-binding and titin-binding fulfill distinct functions in Z-disc cohesion. PLoS Genet 2017;13:e1006880 https://doi.org/10.1371/journal.pgen.1006880 10.1371/journal.pgen.1006880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176.Reinstein E, Gutierrez-Fernandez A, Tzur S, et al. Congenital dilated cardiomyopathy caused by biallelic mutations in Filamin C. Eur J Hum Genet 2016;24:1792-6. https://doi.org/10.1038/ejhg.2016.110 10.1038/ejhg.2016.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Tasca G, Odgerel Z, Monforte M, et al. Novel FLNC mutation in a patient with myofibrillar myopathy in combination with late-onset cerebellar ataxia. Muscle Nerve 2012;46:275-82. https://doi.org/10.1002/mus.23349 10.1002/mus.23349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.Vorgerd M, Van Der Ven PFM, Bruchertseifer V, et al. A mutation in the dimerization domain of filamin c causes a novel type of autosomal dominant myofibrillar myopathy. Am J Hum Gen 2005;77:297-304. https://doi.org/10.1086/431959 10.1086/431959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179.van den Bogaart FJ, Claeys KG, Kley RA, et al. Widening the spectrum of filamin-C myopathy: predominantly proximal myopathy due to the p.A193T mutation in the actin-binding domain of FLNC. Neuromuscul Disord 2017;27:73-7. https://doi.org/10.1016/j.nmd.2016.09.017 10.1016/j.nmd.2016.09.017 [DOI] [PubMed] [Google Scholar]
  • 180.Verdonschot JAJ, Vanhoutte EK, Claes GRF, et al. A mutation update for the FLNC gene in myopathies and cardiomyopathies. Hum Mutat 2020;41:1091-111. https://doi.org/10.1002/humu.24004 10.1002/humu.24004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181.Rossi D, Palmio J, Evila A, et al. A novel FLNC frameshift and an OBSCN variant in a family with distal muscular dystrophy. PLoS One 2017;12:e0186642 https://doi.org/10.1371/journal.pone.0186642 10.1371/journal.pone.0186642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182.Gemelli C, Prada V, Fiorillo C, et al. A novel mutation in the N-terminal acting-binding domain of filamin C protein causing a distal myofibrillar myopathy. J Neurol Sci 2019;398:75-8. https://doi.org/10.1016/j.jns.2019.01.019 10.1016/j.jns.2019.01.019 [DOI] [PubMed] [Google Scholar]
  • 183.Evangelista T, Lornage X, Carlier PG, et al. A heterozygous mutation in the filamin C gene causes an unusual nemaline myopathy with ring fibers. J Neuropathol Exp Neurol 2020;79:908-14. https://doi.org/10.1093/jnen/nlaa052 10.1093/jnen/nlaa052 [DOI] [PubMed] [Google Scholar]
  • 184.Servidei S, Capon F, Spinazzola A, et al. A distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13. Neurology 1999;53:830-7. https://doi.org/10.1212/wnl.53.4.830 10.1212/wnl.53.4.830 [DOI] [PubMed] [Google Scholar]
  • 185.Ruggieri A, Brancati F, Zanotti S, et al. Complete loss of the DNAJB6 G/F domain and novel missense mutations cause distal-onset DNAJB6 myopathy. Acta Neuropathol Commun 2015;3:44 https://doi.org/10.1186/s40478-015-0224-0 10.1186/s40478-015-0224-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186.Hageman J, Rujano MA, van Waarde MA, et al. A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 2010;37:355-69. https://doi.org/10.1016/j.molcel.2010.01.001 10.1016/j.molcel.2010.01.001 [DOI] [PubMed] [Google Scholar]
  • 187.Harms MB, Sommerville RB, Allred P, et al. Exome sequencing reveals DNAJB6 mutations in dominantly-inherited myopathy. Ann Neurol 2012;71:407-16. https://doi.org/10.1002/ana.22683 10.1002/ana.22683 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188.Sarparanta J, Jonson PH, Golzio C, et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nat Genet 2012;44:450-5, S451-452. https://doi.org/10.1038/ng.1103 10.1038/ng.1103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189.Palmio J, Jonson PH, Evila A, et al. Novel mutations in DNAJB6 gene cause a very severe early-onset limb-girdle muscular dystrophy 1D disease. Neuromuscul Disor 2015;25:835-42. https://doi.org/10.1016/j.nmd.2015.07.014 10.1016/j.nmd.2015.07.014 [DOI] [PubMed] [Google Scholar]
  • 190.Bohlega SA, Alfawaz S, Abou-Al-Shaar H, et al. LGMD1D myopathy with cytoplasmic and nuclear inclusions in a Saudi family due to DNAJB6 mutation. Acta Myol 2018;37:221-6. PMID . [PMC free article] [PubMed] [Google Scholar]
  • 191.Zima J, Eaton A, Pal E, et al. Intrafamilial variability of limb-girdle muscular dystrophy, LGMD1D type. Eur J Med Genet 2020;63:103655 https://doi.org/10.1016/j.ejmg.2019.04.012 10.1016/j.ejmg.2019.04.012 [DOI] [PubMed] [Google Scholar]
  • 192.Jonson PH, Palmio J, Johari M, et al. Novel mutations in DNAJB6 cause LGMD1D and distal myopathy in French families. Eur J Neurol 2018;25:790-4. https://doi.org/10.1111/ene.13598 10.1111/ene.13598 [DOI] [PubMed] [Google Scholar]
  • 193.Sandell S, Huovinen S, Palmio J, et al. Diagnostically important muscle pathology in DNAJB6 mutated LGMD1D. Acta Neuropathol Commun 2016;4:9 https://doi.org/10.1186/s40478-016-0276-9 10.1186/s40478-016-0276-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194.Palmio J, Jonson PH, Inoue M, et al. Mutations in the J domain of DNAJB6 cause dominant distal myopathy. Neuromuscul Disord 2020;30:38-46. https://doi.org/10.1016/j.nmd.2019.11.005 10.1016/j.nmd.2019.11.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195.Ghaoui R, Palmio J, Brewer J, et al. Mutations in HSPB8 causing a new phenotype of distal myopathy and motor neuropathy. Neurology 2016;86:391-8. https://doi.org/10.1212/WNL.0000000000002324 10.1212/WNL.0000000000002324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196.Carra S, Seguin SJ, Lambert H, et al. HspB8 chaperone activity toward poly(Q)-containing proteins depends on its association with Bag3, a stimulator of macroautophagy. J Biol Chem 2008;283:1437-44. https://doi.org/10.1074/jbc.M706304200 10.1074/jbc.M706304200 [DOI] [PubMed] [Google Scholar]
  • 197.Nakhro K, Park JM, Kim YJ, et al. A novel Lys141Thr mutation in small heat shock protein 22 (HSPB8) gene in Charcot-Marie-Tooth disease type 2L. Neuromuscul Disord 2013;23:656-63. https://doi.org/10.1016/j.nmd.2013.05.009 10.1016/j.nmd.2013.05.009 [DOI] [PubMed] [Google Scholar]
  • 198.Rusmini P, Cristofani R, Galbiati M, et al. The Role of the Heat Shock Protein B8 (HSPB8) in Motoneuron Diseases Front Mol Neurosci 2017;10:176 https://doi.org/10.3389/fnmol.2017.00176 10.3389/fnmol.2017.00176 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199.Echaniz-Laguna A, Geuens T, Petiot P, et al. Axonal neuropathies due to mutations in small heat shock proteins: clinical, genetic, and functional insights into novel mutations. Hum Mutat 2017;38:556-68. https://doi.org/10.1002/humu.23189 10.1002/humu.23189 [DOI] [PubMed] [Google Scholar]
  • 200.Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004;36:597-601. https://doi.org/10.1038/ng1328 10.1038/ng1328 [DOI] [PubMed] [Google Scholar]
  • 201.Tang BS, Zhao GH, Luo W, et al. Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet 2005;116:222-4. https://doi.org/10.1007/s00439-004-1218-3 10.1007/s00439-004-1218-3 [DOI] [PubMed] [Google Scholar]
  • 202.Al-Tahan S, Weiss L, Yu H, et al. New family with HSPB8-associated autosomal dominant rimmed vacuolar myopathy. Neurol Genet 2019;5:e349 https://doi.org/10.1212/NXG.0000000000000349 10.1212/NXG.0000000000000349 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203.Echaniz-Laguna A, Lornage X, Lannes B, et al. HSPB8 haploinsufficiency causes dominant adult-onset axial and distal myopathy. Acta Neuropathol 2017;134:163-5. https://doi.org/10.1007/s00401-017-1724-8 10.1007/s00401-017-1724-8 [DOI] [PubMed] [Google Scholar]
  • 204.Cortese A, Laura M, Casali C, et al. Altered TDP-43-dependent splicing in HSPB8-related distal hereditary motor neuropathy and myofibrillar myopathy. Eur J Neurol 2018;25:154-63. https://doi.org/10.1111/ene.13478 10.1111/ene.13478 [DOI] [PubMed] [Google Scholar]
  • 205.Nicolau S, Liewluck T, Elliott JL, et al. A novel heterozygous mutation in the C-terminal region of HSPB8 leads to limb-girdle rimmed vacuolar myopathy. Neuromuscul Disord 2020;30:236-40. https://doi.org/10.1016/j.nmd.2020.02.005 10.1016/j.nmd.2020.02.005 [DOI] [PubMed] [Google Scholar]
  • 206.Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet 2010;86:213-21. https://doi.org/10.1016/j.ajhg.2009.12.013 10.1016/j.ajhg.2009.12.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 207.Penttila S, Palmio J, Suominen T, et al. Eight new mutations and the expanding phenotype variability in muscular dystrophy caused by ANO5. Neurology 2012;78:897-903. https://doi.org/10.1212/WNL.0b013e31824c4682 10.1212/WNL.0b013e31824c4682 [DOI] [PubMed] [Google Scholar]
  • 208.Sarkozy A, Deschauer M, Carlier RY, et al. Muscle MRI findings in limb girdle muscular dystrophy type 2L. Neuromuscul Disord 2012;22(Suppl 2):S122-9. https://doi.org/10.1016/j.nmd.2012.05.012 10.1016/j.nmd.2012.05.012 [DOI] [PubMed] [Google Scholar]
  • 209.Whitlock JM, Yu K, Cui YY, et al. Anoctamin 5/TMEM16E facilitates muscle precursor cell fusion. J Gen Physiol 2018;150:1498-509. https://doi.org/10.1085/jgp.201812097 10.1085/jgp.201812097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210.Griffin DA, Johnson RW, Whitlock JM, et al. Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophy. Hum Mol Genet 2016;25:1900-11. https://doi.org/10.1093/hmg/ddw063 10.1093/hmg/ddw063 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 211.Topf A, Johnson K, Bates A, et al. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. Genet Med 2020;22:1478-88. https://doi.org/10.1038/s41436-020-0840-3 10.1038/s41436-020-0840-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 212.Savarese M, Di Fruscio G, Tasca G, et al. Next generation sequencing on patients with LGMD and nonspecific myopathies: Findings associated with ANO5 mutations. Neuromuscul Disord 2015;25:533-41. https://doi.org/10.1016/j.nmd.2015.03.011 10.1016/j.nmd.2015.03.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213.van der Kooi AJ, Ten Dam L, Frankhuizen WS, et al. ANO5 mutations in the Dutch limb girdle muscular dystrophy population. Neuromuscul Disord 2013;23:456-60. https://doi.org/10.1016/j.nmd.2013.03.012 10.1016/j.nmd.2013.03.012 [DOI] [PubMed] [Google Scholar]
  • 214.Schneider I, Stoltenburg G, Deschauer M, et al. Limb girdle muscular dystrophy type 2L presenting as necrotizing myopathy. Acta Myol 2014;33:19-21. PMID . [PMC free article] [PubMed] [Google Scholar]
  • 215.Vihola A, Luque H, Savarese M, et al. Diagnostic anoctamin-5 protein defect in patients with ANO5-mutated muscular dystrophy. Neuropathol Appl Neurobiol 2018;44:441-8. https://doi.org/10.1111/nan.12410 10.1111/nan.12410 [DOI] [PubMed] [Google Scholar]
  • 216.Jarmula A, Lusakowska A, Fichna JP, et al. ANO5 mutations in the Polish limb girdle muscular dystrophy patients: effects on the protein structure. Sci Rep 2019;9:11533 https://doi.org/10.1038/s41598-019-47849-3 10.1038/s41598-019-47849-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 217.Vazquez J, Lefeuvre C, Escobar RE, et al. Phenotypic spectrum of myopathies with recessive anoctamin-5 mutations. J Neuromuscul Di 2020;7:443-51. https://doi.org/10.3233/JND-200515 10.3233/JND-200515 [DOI] [PubMed] [Google Scholar]
  • 218.Panades-de Oliveira L, Bermejo-Guerrero L, de Fuenmayor-Fernandez de la Hoz CP, et al. Persistent asymptomatic or mild symptomatic hyperCKemia due to mutations in ANO5: the mildest end of the anoctaminopathies spectrum. J Neurol 2020;267:2546-55. https://doi.org/10.1007/s00415-020-09872-7 10.1007/s00415-020-09872-7 [DOI] [PubMed] [Google Scholar]
  • 219.Silva AMS, Coimbra-Neto AR, Souza PVS, et al. Clinical and molecular findings in a cohort of ANO5-related myopathy. Ann Clin Transl Neurol 2019;6:1225-38. https://doi.org/10.1002/acn3.50801 10.1002/acn3.50801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220.Cai S, Gao M, Xi J, et al. Clinical spectrum and gene mutations in a Chinese cohort with anoctaminopathy. Neuromuscul Disord 2019;29:628-33. https://doi.org/10.1016/j.nmd.2019.06.005 10.1016/j.nmd.2019.06.005 [DOI] [PubMed] [Google Scholar]
  • 221.Papadopoulos C, LaforEt P, Nectoux J, et al. Hyperckemia and myalgia are common presentations of anoctamin-5-related myopathy in French patients. Muscle Nerve 2017;56:1096-100. https://doi.org/10.1002/mus.25608 10.1002/mus.25608 [DOI] [PubMed] [Google Scholar]
  • 222.Tsutsumi S, Kamata N, Vokes TJ, et al. The novel gene encoding a putative transmembrane protein is mutated in gnathodiaphyseal dysplasia (GDD). Am J Hum Genet 2004;74:1255-61. https://doi.org/10.1086/421527 10.1086/421527 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 223.Jin L, Liu Y, Sun F, et al. Three novel ANO5 missense mutations in Caucasian and Chinese families and sporadic cases with gnathodiaphyseal dysplasia. Sci Rep 2017;7:40935 https://doi.org/10.1038/srep40935 10.1038/srep40935 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224.Jokela M, Tasca G, Vihola A, et al. An unusual ryanodine receptor 1 (RYR1) phenotype: Mild calf-predominant myopathy. Neurology 2019;92:e1600-9. https://doi.org/10.1212/WNL.0000000000007246 10.1212/WNL.0000000000007246 [DOI] [PubMed] [Google Scholar]
  • 225.Dlamini N, Voermans NC, Lillis S, et al. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscul Disord 2013;23:540-8. https://doi.org/10.1016/j.nmd.2013.03.008 10.1016/j.nmd.2013.03.008 [DOI] [PubMed] [Google Scholar]
  • 226.Jungbluth H, Müller CR, Halliger-Keller B, et al. Autosomal recessive inheritance of RYR1 mutations in a congenital myopathy with cores. Neurology 2002;59:284-7. https://doi.org/10.1212/WNL.59.2.284 10.1212/WNL.59.2.284 [DOI] [PubMed] [Google Scholar]
  • 227.Mathews KD, Moore SA. Multiminicore myopathy, central core disease, malignant hyperthermia susceptibility, and RYR1 mutations: one disease with many faces? Arch Neurol 2004;61:27-9. https://doi.org/10.1001/archneur.61.1.27 10.1001/archneur.61.1.27 [DOI] [PubMed] [Google Scholar]
  • 228.Monnier N, Ferreiro A, Marty I, et al. A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Hum Mol Genet 2003;12:1171-8.https://doi.org/10.1093/hmg/ddg121 10.1093/hmg/ddg121 [DOI] [PubMed] [Google Scholar]
  • 229.Matthews E, Neuwirth C, Jaffer F, et al. Atypical periodic paralysis and myalgia: a novel RYR1 phenotype. Neurology 2018;90:e412-8. https://doi.org/10.1212/WNL.0000000000004894 10.1212/WNL.0000000000004894 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230.Jungbluth H, Zhou H, Sewry CA, et al. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2007;17:338-45. https://doi.org/10.1016/j.nmd.2007.01.016 10.1016/j.nmd.2007.01.016 [DOI] [PubMed] [Google Scholar]
  • 231.Jungbluth H, Dowling JJ, Ferreiro A, Muntoni F, Consortium RYRM. 217th ENMC International Workshop: RYR1-related myopathies, Naarden, The Netherlands, 29-31 January 2016. Neuromuscul Disord 2016;26:624-33. https://doi.org/10.1016/j.nmd.2016.06.001 10.1016/j.nmd.2016.06.001 [DOI] [PubMed] [Google Scholar]
  • 232.Clarke NF, Waddell LB, Cooper ST, et al. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Hum Mut 2010;31:e1544-550. https://doi.org/10.1002/humu.21278 10.1002/humu.21278 [DOI] [PubMed] [Google Scholar]
  • 233.Loseth S, Voermans NC, Torbergsen T, et al. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. J Neurol 2013;260:1504-10. https://doi.org/10.1007/s00415-012-6817-7 10.1007/s00415-012-6817-7 [DOI] [PubMed] [Google Scholar]
  • 234.Dowling JJ, Lillis S, Amburgey K, et al. King-Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul Disord 2011;21:420-7. https://doi.org/10.1016/j.nmd.2011.03.006 10.1016/j.nmd.2011.03.006 [DOI] [PubMed] [Google Scholar]
  • 235.Kossugue PM, Paim JF, Navarro MM, et al. Central core disease due to recessive mutations in RYR1 gene: is it more common than described? Muscle Nerve 2007;35:670-4. https://doi.org/10.1002/mus.20715 10.1002/mus.20715 [DOI] [PubMed] [Google Scholar]
  • 236.Laughlin RS, Niu Z, Wieben E, et al. RYR1 causing distal myopathy. Mol Genet Genomic Med 2017;5:800-4. https://doi.org/10.1002/mgg3.338 10.1002/mgg3.338 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237.Laing NG, Laing BA, Meredith C, et al. Autosomal dominant distal myopathy: linkage to chromosome 14. Am J Hum Genet 1995;56:422-7. PMID [PMC free article] [PubMed] [Google Scholar]
  • 238.Lamont PJ, Udd B, Mastaglia FL, et al. Laing early onset distal myopathy: slow myosin defect with variable abnormalities on muscle biopsy. J Neurol Neurosurg Psychiatry 2006;77:208-15. https://doi.org/10.1136/jnnp.2005.073825 10.1136/jnnp.2005.073825 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 239.Tasca G, Ricci E, Penttila S, et al. New phenotype and pathology features in MYH7-related distal myopathy. Neuromuscul Disord 2012;22:640-7. https://doi.org/10.1016/j.nmd.2012.03.003 10.1016/j.nmd.2012.03.003 [DOI] [PubMed] [Google Scholar]
  • 240.Quijano-Roy S, Carlier RY, Fischer D. Muscle imaging in congenital myopathies. Seminars in pediatric neurology. 2011;18:221-9. https://doi.org/10.1016/j.spen.2011.10.003 10.1016/j.spen.2011.10.003 [DOI] [PubMed] [Google Scholar]
  • 241.Dabaj I, Carlier RY, Gomez-Andres D, et al. Clinical and imaging hallmarks of the MYH7-related myopathy with severe axial involvement. Muscle Nerve 2018;58:224-34. https://doi.org/10.1002/mus.26137 10.1002/mus.26137 [DOI] [PubMed] [Google Scholar]
  • 242.Astrea G, Petrucci A, Cassandrini D, et al. Myoimaging in the NGS era: the discovery of a novel mutation in MYH7 in a family with distal myopathy and core-like features – a case report. BMC Med Genet 2016;17:25 https://doi.org/10.1186/s12881-016-0288-0 10.1186/s12881-016-0288-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 243.Meredith C, Herrmann R, Parry C, et al. Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause Laing early-onset distal myopathy (MPD1). Am J Hum Genet 2004;75:703-8. https://doi.org/10.1086/424760 10.1086/424760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 244.Fiorillo C, Astrea G, Savarese M, et al. MYH7-related myopathies: clinical, histopathological and imaging findings in a cohort of Italian patients. Orphanet J Rare Dis 2016;11:91 https://doi.org/10.1186/s13023-016-0476-1 10.1186/s13023-016-0476-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 245.Carbonell-Corvillo P, Tristan-Clavijo E, Cabrera-Serrano M, et al. A novel MYH7 founder mutation causing Laing distal myopathy in Southern Spain. Neuromuscul Disord 2018;28:828-36. https://doi.org/10.1016/j.nmd.2018.07.006 10.1016/j.nmd.2018.07.006 [DOI] [PubMed] [Google Scholar]
  • 246.Banfai Z, Hadzsiev K, Pal E, et al. Novel phenotypic variant in the MYH7 spectrum due to a stop-loss mutation in the C-terminal region: a case report. BMC Med Genet 2017;18:105 https://doi.org/10.1186/s12881-017-0463-y 10.1186/s12881-017-0463-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 247.Feinstein-Linial M, Buvoli M, Buvoli A, et al. Two novel MYH7 proline substitutions cause Laing Distal Myopathy-like phenotypes with variable expressivity and neck extensor contracture. BMC Med Genet 2016;17:57 https://doi.org/10.1186/s12881-016-0315-1 10.1186/s12881-016-0315-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 248.Surikova Y, Filatova A, Polyak M, et al. Common pathogenic mechanism in patients with dropped head syndrome caused by different mutations in the MYH7 gene. Gene 2019;697:159-64. https://doi.org/10.1016/j.gene.2019.02.011 10.1016/j.gene.2019.02.011 [DOI] [PubMed] [Google Scholar]
  • 249.Das KJ, Ingles J, Bagnall RD, et al. Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment. Genet Med 2014;16:286-93. https://doi.org/10.1038/gim.2013.138 10.1038/gim.2013.138 [DOI] [PubMed] [Google Scholar]
  • 250.Morales A, Kinnamon DD, Jordan E, et al. Variant interpretation for dilated cardiomyopathy: refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. Circ Genom Precis Med 2020;13:e002480 https://doi.org/10.1161/CIRCGEN.119.002480 10.1161/CIRCGEN.119.002480 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 251.Mattivi CL, Bos JM, Bagnall RD, et al. Clinical utility of a phenotype-enhanced MYH7-specific variant classification framework in hypertrophic cardiomyopathy genetic testing. Circ Genom Precis Med 2020;13:453-9. https://doi.org/10.1161/CIRCGEN.120.003039 10.1161/CIRCGEN.120.003039 [DOI] [PubMed] [Google Scholar]
  • 252.Muelas N, Hackman P, Luque H, et al. MYH7 gene tail mutation causing myopathic profiles beyond Laing distal myopathy. Neurology 2010;75:732-41. https://doi.org/10.1212/WNL.0b013e3181eee4d5 10.1212/WNL.0b013e3181eee4d5 [DOI] [PubMed] [Google Scholar]
  • 253.Negrao L, Machado R, Lourenco M, et al. Laing early-onset distal myopathy with subsarcolemmal hyaline bodies caused by a novel variant in the MYH7 gene. Acta Myol 2020;39:24-8. https://doi.org/10.36185/2532-1900-004 10.36185/2532-1900-004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 254.Beecroft SJ, van de Locht M, de Winter JM, et al. Recessive MYH7-related myopathy in two families. Neuromuscul Disord 2019;29:456-67. https://doi.org/10.1016/j.nmd.2019.04.002 10.1016/j.nmd.2019.04.002 [DOI] [PubMed] [Google Scholar]
  • 255.Tajsharghi H, Oldfors A, Macleod DP, et al. Homozygous mutation in MYH7 in myosin storage myopathy and cardiomyopathy. Neurology 2007;68:962 https://doi.org/10.1212/01.wnl.0000257131.13438.2c 10.1212/01.wnl.0000257131.13438.2c [DOI] [PubMed] [Google Scholar]
  • 256.Yuceyar N, Ayhan O, Karasoy H, et al. Homozygous MYH7 R1820W mutation results in recessive myosin storage myopathy: scapuloperoneal and respiratory weakness with dilated cardiomyopathy. Neuromuscul Disord 2015;25:340-4. https://doi.org/10.1016/j.nmd.2015.01.007 10.1016/j.nmd.2015.01.007 [DOI] [PubMed] [Google Scholar]
  • 257.Lehtokari VL, Pelin K, Herczegfalvi A, et al. Nemaline myopathy caused by mutations in the nebulin gene may present as a distal myopathy. Neuromuscul Disord 2011;21:556-62. https://doi.org/10.1016/j.nmd.2011.05.012 10.1016/j.nmd.2011.05.012 [DOI] [PubMed] [Google Scholar]
  • 258.Wallgren-Pettersson C, Lehtokari VL, Kalimo H, et al. Distal myopathy caused by homozygous missense mutations in the nebulin gene. Brain 2007;130(Pt 6):1465-76. https://doi.org/10.1093/brain/awm094 10.1093/brain/awm094 [DOI] [PubMed] [Google Scholar]
  • 259.Romero NB, Lehtokari VL, Quijano-Roy S, et al. Core-rod myopathy caused by mutations in the nebulin gene. Neurology 2009;73:1159-61. https://doi.org/10.1212/WNL.0b013e3181bacf45 10.1212/WNL.0b013e3181bacf45 [DOI] [PubMed] [Google Scholar]
  • 260.Kiiski KJ, Lehtokari VL, Vihola AK, et al. Dominantly inherited distal nemaline/cap myopathy caused by a large deletion in the nebulin gene. Neuromuscul Disord 2019;29:97-107. https://doi.org/10.1016/j.nmd.2018.12.007 10.1016/j.nmd.2018.12.007 [DOI] [PubMed] [Google Scholar]
  • 261.Kontrogianni-Konstantopoulos A, Ackermann MA, Bowman AL, et al. Muscle giants: molecular scaffolds in sarcomerogenesis. Physiol Rev 2009;89:1217-67. https://doi.org/10.1152/physrev.00017.2009 10.1152/physrev.00017.2009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 262.Bang ML, Caremani M, Brunello E, et al. Nebulin plays a direct role in promoting strong actin-myosin interactions. FASEB J 2009;23:4117-25. https://doi.org/10.1096/fj.09-137729 10.1096/fj.09-137729 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 263.Wallgren-Pettersson C, Pelin K, Nowak KJ, et al. Genotype-phenotype correlations in nemaline myopathy caused by mutations in the genes for nebulin and skeletal muscle α-actin. Neuromuscular Disorders. 2004;14:461-70. https://doi.org/10.1016/j.nmd.2004.03.006 10.1016/j.nmd.2004.03.006 [DOI] [PubMed] [Google Scholar]
  • 264.Lehtokari VL, Kiiski K, Sandaradura SA, et al. Mutation update: the spectra of nebulin variants and associated myopathies. Hum Mut 2014;35:1418-26. https://doi.org/10.1002/humu.22693 10.1002/humu.22693 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 265.Feingold-Zadok M, Chitayat D, Chong K, et al. Mutations in the NEB gene cause fetal akinesia/arthrogryposis multiplex congenita. Prenat Diagn 2017;37:144-50. https://doi.org/10.1002/pd.4977 10.1002/pd.4977 [DOI] [PubMed] [Google Scholar]
  • 266.Abdalla E, Ravenscroft G, Zayed L, et al. Lethal multiple pterygium syndrome: a severe phenotype associated with a novel mutation in the nebulin gene. Neuromuscul Disord 2017;27:537-41. https://doi.org/10.1016/j.nmd.2017.01.013 10.1016/j.nmd.2017.01.013 [DOI] [PubMed] [Google Scholar]
  • 267.Kiiski K, Lehtokari VL, Loytynoja A, et al. A recurrent copy number variation of the NEB triplicate region: only revealed by the targeted nemaline myopathy CGH array. Eur J Hum Genet 2016;24:574-80. https://doi.org/10.1038/ejhg.2015.166 10.1038/ejhg.2015.166 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 268.Hamanaka K, Miyatake S, Koshimizu E, et al. RNA sequencing solved the most common but unrecognized NEB pathogenic variant in Japanese nemaline myopathy. Genet Me 2019;21:1629-38. https://doi.org/10.1038/s41436-018-0360-6 10.1038/s41436-018-0360-6 [DOI] [PubMed] [Google Scholar]
  • 269.Park HJ, Hong YB, Choi YC, et al. ADSSL1 mutation relevant to autosomal recessive adolescent onset distal myopathy. Ann Neurol 2016;79:231-43. https://doi.org/10.1002/ana.24550 10.1002/ana.24550 [DOI] [PubMed] [Google Scholar]
  • 270.Park HJ, Lee JE, Choi GS, et al. Electron microscopy pathology of ADSSL1 myopathy. J Clin Neurol 2017;13:105-6. https://doi.org/10.3988/jcn.2017.13.1.105 10.3988/jcn.2017.13.1.105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 271.Sun H, Li N, Wang X, et al. Molecular cloning and characterization of a novel muscle adenylosuccinate synthetase, AdSSL1, from human bone marrow stromal cells. Mol Cell Biochem 2005;269:85-94. https://doi.org/10.1007/s11010-005-2539-9 10.1007/s11010-005-2539-9 [DOI] [PubMed] [Google Scholar]
  • 272.Lipps G, Krauss G. Adenylosuccinate synthase from Saccharomyces cerevisiae: homologous overexpression, purification and characterization of the recombinant protein. Biochem J 1999;341(Pt 3):537-43 (https://www.ncbi.nlm.nih.gov/pubmed/10417315. Published 1999/07/27). [PMC free article] [PubMed] [Google Scholar]
  • 273.Park HJ, Shin HY, Kim S, et al. Distal myopathy with ADSSL1 mutations in Korean patients. Neuromuscul Disord 2017;27:465-72. https://doi.org/10.1016/j.nmd.2017.02.004 10.1016/j.nmd.2017.02.004 [DOI] [PubMed] [Google Scholar]
  • 274.Mroczek M, Durmus H, Bijarnia-Mahay S, et al. Expanding the disease phenotype of ADSSL1-associated myopathy in non-Korean patients. Neuromuscul Disord 2020;30:310-4. https://doi.org/10.1016/j.nmd.2020.02.006 10.1016/j.nmd.2020.02.006 [DOI] [PubMed] [Google Scholar]
  • 275.Cirak S, Von Deimling F, Sachdev S, et al. Kelch-like homologue 9 mutation is associated with an early onset autosomal dominant distal myopathy. Brain 2010;133:2123-35. https://doi.org/10.1093/brain/awq108 10.1093/brain/awq108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 276.Tateyama M, Aoki M, Nishino I, et al. Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. Neurolog 2002;58:323-5. https://doi.org/10.1212/WNL.58.2.323 10.1212/WNL.58.2.323 [DOI] [PubMed] [Google Scholar]
  • 277.Chen J, Zeng W, Han C, et al. Mutation in the caveolin-3 gene causes asymmetrical distal myopathy. Neuropathology 2016;36:485-9. https://doi.org/10.1111/neup.12297 10.1111/neup.12297 [DOI] [PubMed] [Google Scholar]
  • 278.Gonzalez-Perez P, Gallano P, Gonzalez-Quereda L, et al. Phenotypic variability in a Spanish family with a caveolin-3 mutation. J Neurol Sci 2009;276:95-8. https://doi.org/10.1016/j.jns.2008.09.009 10.1016/j.jns.2008.09.009 [DOI] [PubMed] [Google Scholar]
  • 279.Fulizio L, Nascimbeni AC, Fanin M, et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat 2005;25:82-9. https://doi.org/10.1002/humu.20119 10.1002/humu.20119 [DOI] [PubMed] [Google Scholar]
  • 280.Carbone I, Bruno C, Sotgia F, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000;5:1373-6. https://doi.org/10.1212/wnl.54.6.1373 10.1212/wnl.54.6.1373 [DOI] [PubMed] [Google Scholar]
  • 281.Vorgerd M, Bolz H, Patzold T, et al. Phenotypic variability in rippling muscle disease. Neurology 1999;52:1453-9. https://doi.org/10.1212/wnl.52.7.1453 10.1212/wnl.52.7.1453 [DOI] [PubMed] [Google Scholar]
  • 282.Kubisch C, Schoser BG, von During M, et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol 2003;53:512-20. https://doi.org/10.1002/ana.10501 10.1002/ana.10501 [DOI] [PubMed] [Google Scholar]
  • 283.Ishiguro K, Nakayama T, Yoshioka M, et al. Characteristic findings of skeletal muscle MRI in caveolinopathies. Neuromuscul Disord 2018;28:857-62. https://doi.org/10.1016/j.nmd.2018.07.010 10.1016/j.nmd.2018.07.010 [DOI] [PubMed] [Google Scholar]
  • 284.Macias A, Gambin T, Szafranski P, et al. CAV3 mutation in a patient with transient hyperCKemia and myalgia. Neurol Neurochir Pol 2016;50:468-73. https://doi.org/10.1016/j.pjnns.2016.06.008 10.1016/j.pjnns.2016.06.008 [DOI] [PubMed] [Google Scholar]
  • 285.Scalco RS, Gardiner AR, Pitceathly RD, et al. CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: expanding the phenotypic spectrum of caveolinopathies. Neuromuscul Disord 2016;26:504-10. https://doi.org/10.1016/j.nmd.2016.05.006 10.1016/j.nmd.2016.05.006 [DOI] [PubMed] [Google Scholar]
  • 286.Vatta M, Ackerman MJ, Ye B, et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006;114:2104-12. https://doi.org/10.1161/CIRCULATIONAHA.106.635268 10.1161/CIRCULATIONAHA.106.635268 [DOI] [PubMed] [Google Scholar]
  • 287.Hayashi T, Arimura T, Ueda K, et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2004;313:178-84. https://doi.org/10.1016/j.bbrc.2003.11.101 10.1016/j.bbrc.2003.11.101 [DOI] [PubMed] [Google Scholar]
  • 288.Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet 1998;18:365-8. https://doi.org/10.1038/ng0498-365 10.1038/ng0498-365 [DOI] [PubMed] [Google Scholar]
  • 289.Bitoun M, Maugenre S, Jeannet PY, et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat Genet 2005;37:1207-9. https://doi.org/10.1038/ng1657 10.1038/ng1657 [DOI] [PubMed] [Google Scholar]
  • 290.Bitoun M, Bevilacqua JA, Prudhon B, et al. Dynamin 2 mutations cause sporadic centronuclear myopathy with neonatal onset. Ann Neurol 2007;62:666-70. https://doi.org/10.1002/ana.21235 10.1002/ana.21235 [DOI] [PubMed] [Google Scholar]
  • 291.Fischer D, Herasse M, Bitoun M, et al. Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain 2006;129(Pt 6):1463-9. https://doi.org/10.1093/brain/awl071 10.1093/brain/awl071 [DOI] [PubMed] [Google Scholar]
  • 292.Bitoun M, Bevilacqua JA, Eymard B, et al. A new centronuclear myopathy phenotype due to a novel dynamin 2 mutation. Neurology 2009;72:93-5. https://doi.org/10.1212/01.wnl.0000338624.25852.12 10.1212/01.wnl.0000338624.25852.12 [DOI] [PubMed] [Google Scholar]
  • 293.Bohm J, Biancalana V, Dechene ET, et al. Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012;33:949-59. https://doi.org/10.1002/humu.22067 10.1002/humu.22067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 294.Chen S, Huang P, Qiu Y, et al. Phenotype variability and histopathological findings in patients with a novel DNM2 mutation. Neuropathology 2018;38:34-40. https://doi.org/10.1111/neup.12432 10.1111/neup.12432 [DOI] [PubMed] [Google Scholar]
  • 295.Lin P, Liu X, Zhao D, et al. DNM2 mutations in Chinese Han patients with centronuclear myopathy. Neurol Sci 2016;37:995-8. https://doi.org/10.1007/s10072-016-2513-1 10.1007/s10072-016-2513-1 [DOI] [PubMed] [Google Scholar]
  • 296.Abath Neto O, Martins Cde A, Carvalho M, et al. DNM2 mutations in a cohort of sporadic patients with centronuclear myopathy. Genet Mol Biol 2015;38:147-1. https://doi.org/10.1590/S1415-4757382220140238 10.1590/S1415-4757382220140238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 297.Casar-Borota O, Jacobsson J, Libelius R, et al. A novel dynamin-2 gene mutation associated with a late-onset centronuclear myopathy with necklace fibres. Neuromuscul Disord 2015;25:345-8. https://doi.org/10.1016/j.nmd.2015.01.001 10.1016/j.nmd.2015.01.001 [DOI] [PubMed] [Google Scholar]
  • 298.Catteruccia M, Fattori F, Codemo V, et al. Centronuclear myopathy related to dynamin 2 mutations: clinical, morphological, muscle imaging and genetic features of an Italian cohort. Neuromuscul Disord 2013;23:229-38. https://doi.org/10.1016/j.nmd.2012.12.009 10.1016/j.nmd.2012.12.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 299.Mori-Yoshimura M, Okuma A, Oya Y, et al. Clinicopathological features of centronuclear myopathy in Japanese populations harboring mutations in dynamin 2. Clin Neurol Neurosurg 2012;114:678-83. https://doi.org/10.1016/j.clineuro.2011.10.040 10.1016/j.clineuro.2011.10.040 [DOI] [PubMed] [Google Scholar]
  • 300.Hanisch F, Muller T, Dietz A, et al. Phenotype variability and histopathological findings in centronuclear myopathy due to DNM2 mutations. J Neurol 2011;258:1085-90. https://doi.org/10.1007/s00415-010-5889-5 10.1007/s00415-010-5889-5 [DOI] [PubMed] [Google Scholar]
  • 301.Biancalana V, Romero NB, Thuestad IJ, et al. Some DNM2 mutations cause extremely severe congenital myopathy and phenocopy myotubular myopathy. Acta Neuropathol Commun 2018;6:93 https://doi.org/10.1186/s40478-018-0593-2 10.1186/s40478-018-0593-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 302.Gallardo E, Claeys KG, Nelis E, et al. Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation. J Neuro 2008;255:986-92. https://doi.org/10.1007/s00415-008-0808-8 10.1007/s00415-008-0808-8 [DOI] [PubMed] [Google Scholar]
  • 303.Ramachandran R, Schmid SL. The dynamin superfamily. Curr Biol 2018;28:r411-6. https://doi.org/10.1016/j.cub.2017.12.013 10.1016/j.cub.2017.12.013 [DOI] [PubMed] [Google Scholar]
  • 304.Lee JS, Ismail AM, Lee JY, et al. Impact of dynamin 2 on adenovirus nuclear entry. Virology 2019;529:43-56. https://doi.org/10.1016/j.virol.2019.01.008 10.1016/j.virol.2019.01.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 305.Zhao M, Maani N, Dowling JJ. Dynamin 2 (DNM2) as cause of, and modifier for, human neuromuscular disease. Neurotherapeutics 2018;15:966-75. https://doi.org/10.1007/s13311-018-00686-0 10.1007/s13311-018-00686-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 306.González-Jamett AM, Baez-Matus X, Olivares MJ, et al. Dynamin-2 mutations linked to centronuclear myopathy impair actin-dependent trafficking in muscle cells. Scientific Reports 2017;7 https://doi.org/10.1038/s41598-017-04418-w 10.1038/s41598-017-04418-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 307.Durieux AC, Vignaud A, Prudhon B, et al. A centronuclear myopathy-dynamin 2 mutation impairs skeletal muscle structure and function in mice. Hum Mol Genet 2010;19:4820-36. https://doi.org/10.1093/hmg/ddq413 10.1093/hmg/ddq413 [DOI] [PubMed] [Google Scholar]
  • 308.Claeys KG, Zuchner S, Kennerson M, et al. Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain 2009;132(Pt 7):1741-52. https://doi.org/10.1093/brain/awp115 10.1093/brain/awp115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 309.Koutsopoulos OS, Kretz C, Weller CM, et al. Dynamin 2 homozygous mutation in humans with a lethal congenital syndrome. Eur J Hum Genet 2013;21:637-42. https://doi.org/10.1038/ejhg.2012.226 10.1038/ejhg.2012.226 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 310.Lochmuller H, Badowska DM, Thompson R, et al. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet 2018;26:778-85. https://doi.org/10.1038/s41431-018-0115-5 10.1038/s41431-018-0115-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 311.Peterlin B, Gualandi F, Maver A, et al. Genetic testing offer for inherited neuromuscular diseases within the EURO-NMD reference network: a European survey study. PLoS One 2020;15:e0239329 https://doi.org/10.1371/journal.pone.0239329 10.1371/journal.pone.0239329 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 312.Austin CP, Cutillo CM, Lau LPL, et al. Future of Rare Diseases Research 2017-2027: an IRDiRC perspective. Clin Transl Sci 2018;11:21-7. https://doi.org/10.1111/cts.12500 10.1111/cts.12500 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 313.Gonorazky HD, Naumenko S, Ramani AK, et al. Expanding the boundaries of RNA sequencing as a diagnostic tool for rare mendelian disease. Am J Hum Genet 2019;104:466-83. https://doi.org/10.1016/j.ajhg.2019.01.012 10.1016/j.ajhg.2019.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 314.Cummings BB, Marshall JL, Tukiainen T, et al. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. Sci Transl Med 2017;9 https://doi.org/10.1126/scitranslmed.aal5209 10.1126/scitranslmed.aal5209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 315.Matalonga L, Laurie S, Papakonstantinou A, et al. Improved diagnosis of rare disease patients through systematic detection of runs of homozygosity. J Mol Diagn 2020;22:1205-15. https://doi.org/10.1016/j.jmoldx.2020.06.008 10.1016/j.jmoldx.2020.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 316.Mantere T, Kersten S, Hoischen A. Long-read sequencing emerging in medical genetics. Front Genet 2019;10:426 https://doi.org/10.3389/fgene.2019.00426 10.3389/fgene.2019.00426 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 317.Thompson R, Spendiff S, Roos A, et al. Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. Lancet Neurol 2020;19:522-32. https://doi.org/10.1016/S1474-4422(20)30028-4 10.1016/S1474-4422(20)30028-4 [DOI] [PubMed] [Google Scholar]
  • 318.Boycott KM, Hartley T, Biesecker LG, et al. A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell 2019;177:32-7. https://doi.org/10.1016/j.cell.2019.02.040 10.1016/j.cell.2019.02.040 [DOI] [PubMed] [Google Scholar]

Articles from Acta Myologica are provided here courtesy of Pacini Editore

RESOURCES